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This review focuses on the systemic complications of acro-
megaly. Mortality in this disease is increased mostly because
of cardiovascular and respiratory diseases, although cur-
rently neoplastic complications have been questioned as a
relevant cause of increased risk of death. Biventricular hy-
pertrophy, occurring independently of hypertension and met-
abolic complications, is the most frequent cardiac complica-
tion. Diastolic and systolic dysfunction develops along with
disease duration; and other cardiac disorders, such as ar-
rhythmias, valve disease, hypertension, atherosclerosis, and
endothelial dysfunction, are also common in acromegaly. Con-
trol of acromegaly by surgery or pharmacotherapy, especially
somatostatin analogs, improves cardiovascular morbidity.
Respiratory disorders, sleep apnea, and ventilatory dysfunc-
tion are also important contributors in increasing mortality
and are beneficially advantaged by controlling GH and IGF-I
hypersecretion. An increased risk of colonic polyps, which
more frequently recur in patients not controlled after treat-
ment, has been reported by several independent investiga-
tions, although malignancies in other organs have also been
described, but less convincingly than at the gastrointestinal
level. Finally, the most important cause of morbidity and func-
tional disability of the disease is arthropathy, which can be
reversed at an initial stage, but not if the disease is left un-
treated for several years. (Endocrine Reviews 25: 102–152,
2004)
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I. Introduction
IN 1864, THE skull of a woman affected by prosopectasia(derived from the Greek words prosopon, face, and ektasis,
stretching) was described by Verga (1) and added to the
collection of the Anatomical Museum of Modena, Italy. Dur-
ing her lifetime, this patient suffered from typical somatic
disfigurement, arrhythmias, and osteoarthropathy, although
a postmortem examination revealed a giant pituitary (1). In
1881, Brigidi reported a description clinically consistent with
acromegaly from the autopsy of the Italian actor Ghirlenzoni
Abbreviations: ALS, Acid-labile subunit; ANP, atrial natriuretic pep-
tide; Apo, apolipoprotein; CETP, cholesteryl ester transfer protein;
DISH, diffuse idiopathic skeletal hyperostosis; ECG, electrocardiogram;
ER, estrogen receptor; GH-R, GH receptor; HDL, high-density lipopro-
tein; IGFBP, IGF binding protein; IGF-IR, IGF type I receptor; IGT,
impaired glucose tolerance; IMT, intima-media thickness; LAR, long-
acting repeatable; LDL, low-density lipoprotein; Lp-a, lipoprotein-a;
LPL, lipoprotein lipase; MRI, magnetic resonance imaging; PR, proges-
terone receptor; PRL, prolactin; PSA, prostate-specific antigen; SCLC,
small cell lung cancer; SIR, standardized incidence ratio; TGHM, trans-
genic for the GH gene.
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(2). This man had visceromegaly and enlarged hypertrophic
pituitary. However, both Verga and Brigidi misinterpreted
the pathogenesis of the syndrome, which was attributed to
early menopause in the former and to primary bone disease
in the latter case. Five years after Brigidi’s description, Pierre
Marie (3) indicated with acromegaly his observation of two
patients he had treated at the Salpetrie`re Hospital in Paris. At
autopsy, Marie observed visceromegaly and enlarged pitu-
itaries but was uncertain whether pituitary overgrowth was
the cause etiology of such syndrome or whether it reflected
the general process of organomegaly observed in these pa-
tients (3). Afterward, a progressively increasing number of
similar descriptions were provided. Massalongo in 1892 and
Benda in 1900 both indicated the cause of the disease as
originating in the pituitary (2). However, it was only in 1909
that Harvey Cushing (4) reported the remission of clinical
symptoms of acromegaly after partial hypophysectomy, thus
indicating the etiology of the disease and its potential treat-
ment as well. Acromegaly is known to be characterized by
progressive somatic disfigurement and a wide range of sys-
temic manifestations (5, 6). At diagnosis, patients generally
exhibit coarsened facial features, exaggerated growth of
hands and feet, and soft tissue hypertrophy (Table 1). Other
characteristics may include hyperhidrosis, goiter, osteoar-
thritis, carpal tunnel syndrome, fatigue, visual abnormalities,
increased number of skin tags, colon polyps, sleep apnea and
daytime somnolence, reproductive disorders, and cardio-
vascular disease, which most commonly includes cardiac
hypertrophy, hypertension, and moderate arrhythmias, al-
though congestive heart failure occurs more rarely (5–7).
Improvement of surgical procedures, radiotherapy tools,
and the availability of pharmacological compounds active on
somatotroph pituitary cells greatly changed the approach to
this disease that is an extraordinary model to investigate the
pathophysiology of GH and IGF-I actions on virtually all
body organs and systems; several systemic consequences
developing in the course of undiagnosed GH and IGF-I ex-
cess may remain undiagnosed for a long time.
The aim of this review is to focus on the systemic com-
plications of acromegaly, their pathogenesis, and the poten-
tial reversibility after treatment of the primary disease. Be-
cause the disease is rare, prospective mortality data in
patients undergoing modern therapies are still lacking. Nev-
ertheless, both earlier and new data indicate that the in-
creased mortality in acromegaly is mainly due to cardiovas-
cular disease and respiratory impairment (see Section I.A). In
this review, cardiovascular diseases, metabolic complica-
tions closely linked to the increased cardiovascular risk, re-
spiratory abnormalities, and malignancies will by consid-
ered as the first and most relevant cause of mortality,
whereas bone complications will be considered next as the
most important cause of morbidity. A short introduction to
the disease, its development, and management is provided
to better present the specific analysis of single complications
TABLE 1. Clinical features of acromegaly
Direct effects of the tumor
Headache visual impairment Visual loss
Temporal hemianopia of one or both eyes
Quadrandopia
Hyperprolactinemia Mixed tumoral secretion or pituitary stalk section
Hypopituitarism cavernous sinus syndrome Hypothyroidism, hypogonadism, hypocorticism
Systemic effects of GH/IGF-I excess
Soft tissue and skin changes Acral enlargement
Increased skin thickness and soft tissue hyperplasia
Increased sweating
Skin tags and acanthosis nigricans
Cardiovascular features Biventricular hypertrophy
Increased interventricular septum thickness (eccentric hypertrophy)
Diastolic dysfunction at rest and/or systolic dysfunction on effort
Diastolic heart failure
Arrhythmias
Hypertension
Endothelial dysfunction and increased carotid IMT
Metabolic features Impaired fasting glucose
Impaired glucose tolerance
Diabetes mellitus
Insulin resistance
Reduced total cholesterol and increased triglycerides
Increased nitrogen retention
Respiratory features Upper airway obstruction
Macroglossia
Sleep apnea
Ventilatory dysfunction
Bone and joint features Increased articular cartilage thickness
Arthropathy/osteoarthritis
Carpal tunnel syndrome
Osteopenia
Other endocrine consequences Multinodular thyroid goiter
Thyrotoxicosis
Hypercalciuria
Hyperparathyroidism
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and their epidemiology, pathogenesis, and partial or total
reversibility after controlling GH and IGF-I hypersecretion.
A. Epidemiology and causes of mortality in acromegaly
Acromegaly has an estimated annual incidence of three to
four cases per million population and a current estimated
prevalence of 40 cases per million population, which can be
reportedly as high as 90 cases per million population (8–10).
In most cases, chronic GH hypersecretion is caused by a
benign pituitary adenoma (5). Due to its indolent and insid-
ious nature, the diagnosis of acromegaly is usually delayed
for a variable number of years (7). Retrospective epidemio-
logical studies showed that diagnosis can be preceded by
approximately four to 10 or more years of active disease, and
it is likely that today the diagnosis is made earlier than before
because patients present much less with visual field defects
(11). Analysis of determinants of mortality outcome indicates
that approximately 60% of acromegalic patients die from
cardiovascular disease, 25% from respiratory disease, and
15% from malignancies (12–19). The nadir GH value likely
constitutes the most predictive survival index, regardless of
the death cause (13, 15–18). There is compelling evidence
indicating that control of GH levels and/or IGF-I levels nor-
malized for age is associated with improvement of adverse
mortality rates, independent of the type of associated com-
plications (17). Suppression of GH below 5 mU/liter (2.5
g/liter) had been shown already to portend a favorable
mortality outcome (19, 20). In fact, it has been suggested that
overall mortality in patients with acromegaly is correlated
with the degree of GH control (18); mortality rates for cancer
can be stratified according to posttreatment GH levels (18);
and, if GH secretion is controlled, mortality rates become
similar to those recorded in the nonacromegalic population
(13, 18). However, mortality in patients with cardiac disease
at the time of diagnosis occurs within 15 yr in almost 100%
of cases, and only 20% of patients with diabetes and acro-
megaly will survive 20 yr (16). High GH levels, hypertension,
and heart disease constitute the major negative survival de-
terminants in acromegaly (19), whereas symptoms duration
and other factors, including uncontrolled diabetes and/or
dyslipidemia and cancer, account less for mortality (Fig. 1).
Thus, control of GH hypersecretion, hypertension, and heart
disease is relevant to improve the ultimate mortality rates.
B. The clinical basis of increased mortality in acromegaly
As stated above, acromegaly is a disease developing
slowly and insidiously, so that diagnosis is delayed by a
number of years. Sleep apnea and daytime somnolence, re-
productive disorders, and cardiovascular disease, which
most commonly includes cardiac hypertrophy, hyperten-
sion, and moderate arrhythmias, are rather frequent,
whereas congestive heart failure is rarer and occurs during
the long-term exposure to high GH and IGF-I levels (5–7, 21).
In particular, cardiovascular disease contributes significantly
to mortality, and patients with hypertension and diabetes
have the most severe alteration of cardiac function (22, 23);
in a large cohort of 130 patients with acromegaly studied by
echocardiography at diagnosis, we reported that patients
with hypertension but without abnormalities of glucose tol-
erance had a higher prevalence of left ventricular hypertro-
phy and systolic and diastolic dysfunction than patients with
uncomplicated disease (23). Conversely, the role of diabetes
and other metabolic abnormalities in contributing to hyper-
tension and cardiovascular disease in acromegaly is still not
known. Patients with acromegaly are also at increased risk
for arthritis, sleep apnea, and development of neoplastic
lesions, particularly in the colon (19, 24). In the largest cohort
study reported so far, however, cancer did not appear to act
as a major cause of mortality (18). Possible genetic predis-
posing factors and enhanced family risk may be similarly
relevant to the onset of and mortality from neoplastic com-
plications, likely more than GH excess itself. Sleep apnea,
both obstructive and central, is a significant cause of mor-
bidity, closely linked to hypertension (25). Besides the neg-
ative effects of high circulating GH and IGF-I levels, the
tumor mass itself may induce compression of the optic nerve
tract or chiasm, cranial nerve palsies, headache, hydroceph-
alus, as well as various degrees of pituitary function insuf-
ficiency (5, 6). These mass-related complications are typical
of pituitary tumor expansion and so are common to other
tumor types and thus they will be not considered in this
review.
C. The experimental basis for the GH/IGF-I effects at
different body organs
Nearly one century after Verga’s original documentation
(1), Salmon and Daughaday’s findings (26) set the basis for
the somatomedin hypothesis with the identification of liver-
derived serum factor-mediating GH actions on peripheral
tissues. The same serum factor was sequentially termed sul-
fation factor, nonsuppressible insulin-like activity, multipli-
cation-stimulation activity, and eventually IGF-I in indepen-
dent investigations (reviewed in Refs. 27 and 28). The
concept that GH operated on peripheral tissues through en-
docrine IGF-I was successively revised in the early 1980s,
when IGF-I was shown to be expressed ubiquitously in sev-
eral body tissues and its local expression could be modulated
by exogenous GH administration to animals (27, 28). Sub-
sequent studies in preadipocytes and chondrocytes at-
FIG. 1. Depiction of mortality determinants in patients with acro-
megaly. The x-axis reflects the P value (log) as calculated from pub-
lished retrospective reports. [From S. Melmed: J Clin Endocrinol
Metab 86:2929–2934, 2001 (19). Permission granted by The Endo-
crine Society.]
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tempted at discriminating between GH and IGF-I effects in
the periphery and demonstrated that GH promoted cellular
differentiation, whereas IGF-I preferentially induced clonal
expansion, thus introducing the dual effector theory (29).
However, the congruity of the aforementioned theories has
been recently questioned. GH has been found also to mod-
ulate the expression of various growth factors and their re-
ceptors in several tissues, in addition to IGF-I. GH can stim-
ulate directly the proliferation of chondrocytes in the
germinal zone of the growth plate (30), and it promotes the
activation of immediate early gene (i.e., transcription of early
growth response factor-1) in 3T3-F442A preadipocytes (31).
A demonstration that endocrine GH had local effects on cells
originated from studies in mice carrying null mutations for
the IGF-I gene that showed a normal proliferation of growth
plate chondrocytes despite a 35% decrease in longitudinal
bone growth (32). To explain this finding, the authors spec-
ulated that the lack of IGF-I stimulus had likely been replaced
by endogenous GH or, alternatively, by local IGF-II (32).
Recent investigations are now questioning whether liver
IGF-I production actually plays an essential role in postnatal
growth and development. Studies in conditional IGF-I
knockout mouse models obtained with the Cre/loxP recom-
bination system have, in fact, demonstrated that abrogation
of liver IGF-I expression blunts 75% of endocrine IGF-I se-
cretion, increases GH levels in serum likely due to feedback
mechanisms, and preserves postnatal growth and develop-
ment; as a result, autocrine/paracrine IGF-I production
seems to be sufficient for normal growth and development,
although a direct effect of GH on nonhepatic tissues cannot
be excluded (33, 34).
GH action is achieved via its interaction on the cell surface
with its receptor (GH-R) belonging to the family of the cy-
tokine receptors (35), whereas IGF-I belongs to a system of
proteins encompassing IGF-II, the type-I and -II IGF recep-
tors (IGF-IR and -IIR), six IGF binding proteins (IGFBPs),
three families of IGFBP proteases, and nine growth-mediat-
ing factors that share structural similarities in the N-terminus
of the IGFBPs and have therefore also been termed IGFBP-
related proteins (Fig. 2) (28). IGF-I circulates in serum bound
to IGFBP-3 and the acid-labile subunit (ALS) in a 150-kDa
ternary complex, which works both as a reservoir and reg-
ulator of IGF-I biodistribution to peripheral tissues/organs.
Due to the molecular weight of ALS, IGF-I is unable to cross
the endothelium unless it is released from the ternary com-
plex after the proteolysis of IGFBP-3. IGFBP-3 proteolysis
generates fragments with a lower IGF-I binding affinity, and
this is key in the regulation of local IGF-I bioavailability.
Studies in hypophysectomized rats have clearly demon-
strated that all three peptides of the ternary complex are
synthesized in the liver in a GH-dependent fashion, although
a GH-responsive element has only been identified in the ALS
promoter (36). In the liver, hepatocytes are the primary
source for IGF-I and ALS production, whereas IGFBP-3 is
synthesized preferentially in the portal venous and sinusoi-
dal endothelium, as determined by the expression of mRNA
by in situ hybridization histochemistry (37). Due to their GH
dependence, the impairment of total and free IGF-I, IGFBP-3,
and ALS secretion is used for diagnostic purposes in acro-
megaly and GH deficiency (38, 39). Although it has been
shown that both IGF-I and IGFBP-3 elicit multiple cellular
effects both dependently and independently of each other,
ALS does not seem to possess intrinsic biological activity.
The IGF-I cellular effects are achieved through the interaction
of IGF-I with the IGF-IR, a heterotetrameric protein that is
evolutionarily and structurally similar to the insulin receptor
in its - and -subunits (40). The intracellular domains of the
-subunits of IGF-IR possess tyrosine kinase activity and
tyrosine residues that are phosphorylated upon receptor ac-
tivation. The consequence of receptor phosphorylation is the
downstream recruitment of signaling proteins including the
IRS and Shc families of proteins, which in turn activate the
FIG. 2. Representation of the IGF sys-
tem comprising IGFs, IGFBP-1 through
6, IGFBP-related proteins, IGF and
IGFBP cell membrane receptors, and
additional translocation mechanisms
for IGFBP-3 to the nucleus.
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MAPK and phosphatidylinositol 3-kinase pathways, as well
as additional downstream signaling proteins leading to gene
transcription (27). Depending on the preponderance of in-
tracellular IRS or Shc proteins, IGF-I will promote either
cellular proliferation/transformation or differentiation (41).
Noteworthy, the primary role of IGF-I is the regulation of
postnatal growth and the mediation of the growth-promot-
ing effects of GH. The overexpression of bovine, murine, or
rat GH stimulates body growth and increases IGF-I levels in
transgenic mice (42). Similar body growth promoting effects
are produced by human IGF-I overexpression in the mice
liver (43). In contrast, IGF-I null mice suffer from impairment
of fetal growth and development, whereas perinatal viability
is markedly decreased (44). The physiological actions of
IGF-I also encompass increased muscle protein synthesis
(45), in vivo and in vitro stimulation of muscle cell differen-
tiation (40), enhanced glucose uptake in peripheral tissues
(45), bone growth and maturation (46), oligodendrocyte sur-
vival, and neuronal differentiation (47). These effects require
a functionally active IGF-IR, which is essential for normal
embryonic and fetal growth, modulation of cellular apopto-
sis, and the growth, proliferation, and migration of normal
and tumoral cells (48).
Additionally, there is in vitro evidence to suggest that
IGFBP-3 causes antiproliferative and apoptotic effects in
breast, prostate, lung, and colorectal tumoral cell lines in-
dependent of the IGF axis (49). In addition, serum IGFBP-3
levels have been correlated negatively to cancer risk in hu-
man prostate, mammary, and gut neoplasms (50–52). Al-
though uncertainty still exists on the clinical significance of
these observations, demonstration of independent IGFBP-3
actions adds one more puzzling aspect to the dual effector
theory and, more specifically, to the pathophysiology of
acromegaly.
D. Management of acromegaly
An extensive discussion on the current approaches for an
integrated and modern management of acromegaly lies be-
yond the scope of this review. However, because most of the
subsequent parts will refer to the partial or total recovery of
systemic complications of acromegaly after controlling GH/
IGF-I hypersecretion, the most recent advances in the man-
agement of acromegaly will be summarized here.
The optimal treatment for acromegaly should be able to
remove the tumor with resolution of its mass effects, pre-
serve the normal residual pituitary function, prevent recur-
rences, restore normal GH and IGF-I secretion, relieve symp-
toms directly caused by GH excess, and, possibly, prevent
progressive disfigurement, bone expansion, osteoarthritis,
cardiomyopathy, hypertension, insulin resistance, diabetes
mellitus, and lipid abnormalities, thus reversing the unfa-
vorable long-term outcome (6). The treatment options cur-
rently available for such ambitious goals include surgery,
irradiation, and pharmacological suppression of GH levels
by somatostatin analogs or dopamine agonists, and/or by
functional blockade of the GH-R by modified GH analog (53),
which has provided promising results (54, 55). Cure criteria
to evaluate the efficacy of all treatment approaches, except
for the GH-antagonist, are mean integrated 24-h GH levels
less than 2.5 g/liter or no more than 1 g/liter after glucose
load, together with circulating IGF-I levels normalized for
age and gender (20). Clearly, other pituitary hormone defi-
ciencies that may be caused by the tumor and/or by its
treatment must be treated as in other types of pituitary
tumors.
Transsphenoidal adenomectomy remains a milestone
treatment for GH-secreting tumors, but should be performed
only in experienced centers. Moreover, it has been reported
recently that the outcome of surgery when only one surgeon
operates on patients is higher than that observed when more
than one surgeon operates (56, 57). The outcome of surgery
is successful in most microadenomas and enclosed macroad-
enomas, but it remains disappointing in larger adenomas
and negligible in invasive tumors (6, 16, 56, 58). Among 224
consecutive patients, endocrine remission occurred in 72% of
microadenomas, 50% of macroadenomas, and only 17% of
giant adenomas (59). Normalized IGF-I levels with GH levels
below 3 g/liter (60), or 2.5 g/liter (61), were achieved in
59% and 42% of unselected patients, respectively. In mi-
croadenomas, success of surgery was obtained in 61% of
patients (61). Surgery relieves the compression on adjacent
structures such as optic chiasm and ventricles, and it only
rarely causes complications. In fact, in a study including
questionnaires regarding 14 specific complications of trans-
sphenoidal surgery mailed to 3172 neurosurgeons, it was
reported that the mean operative mortality rate was low
(0.9%), anterior pituitary insufficiency and diabetes insipi-
dus were the most common complications (19.4% and 17.8%,
respectively), whereas cerebrospinal fluid fistulas were
found in a low number of cases (3.9%) and other complica-
tions, such as carotid artery injuries, hypothalamic injuries,
loss of vision, and meningitis, occurred in 1–2% of cases (62).
In another study (63), pituitary failure after surgery was
confirmed to be the most frequent complication occurring in
up to 30% of patients with macroadenomas. A controversy
exists on the usefulness of a short preoperative drug treat-
ment to improve surgical outcome (for review, see Refs. 6 and
64); we observed that a 6-month treatment with octreotide
preoperatively improved metabolic and hemodynamic pa-
rameters and reduced the duration of hospital stay in acro-
megalic patients (65). Recently, to provide a technical refine-
ment in pituitary surgery, a one-nostril endoscopic
endonasal transsphenoidal procedure has been proposed to
reduce the damage to nose and sphenoid sinus and to im-
prove the management of the pituitary region (66). Interest-
ingly, postsurgical complications using this technique are
likely to be low compared with classical microscopical ap-
proach (67). In fact, among 146 consecutively treated patients
who underwent an endoscopic endonasal transsphenoidal
approach to the sellar region for resection of pituitary ade-
nomas between January 1997 and July 2001, complications
(divided into groups, i.e., nasofacial, sphenoid sinus, sella
turcica, supra or parasellar, and endocrine) were decreased
in their incidence compared with large historical series of the
traditional microsurgical transsphenoidal approach (67). The
overview inside the anatomy facilitated by the endoscope
and the consequent decreased surgical trauma can be taken
as explanation for such positive findings.
Irradiation of GH-secreting pituitary tumor should be re-
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served to patients in whom surgery is contraindicated or
unsuccessful and medical treatment fails to control persistent
hormone hypersecretion due to a remnant tumor (68). Mul-
tiple methods for delivery of radiation are currently used,
including external radiation, proton beam, -particles, and
interstitial radiotherapy. All seem to induce similar cure
rates. The greatest fall in GH levels occurs within the first 2
yr, followed by a gradual decline thereafter for 10 yr (69).
Earlier observations that pituitary irradiation normalized
IGF-I concentrations only in a minority of patients (70, 71)
have not been confirmed by later studies reporting higher
cure rates (72, 73). Furthermore, the occurrence of severe
complications, such as cranial nerve palsies, optic neuritis,
impaired memory, lethargy, and tissue necrosis has de-
creased with modern techniques. However, damage of the
normal hypothalamic-pituitary region results in hypopitu-
itarism in more than half of patients within 10 yr (6, 63, 68,
69). Gamma-knife radiosurgery has been used as adjuvant
treatment for pituitary adenomas in selected cases with
promising results (74), but definitive data are still lacking.
Bromocriptine, the first and likely still the most widely
used dopamine agonist in acromegaly, lowered GH levels
below 10 g/liter and 5 g/liter in 50% and 10–20%, re-
spectively, of over 500 patients with acromegaly included in
a metaanalysis from 28 published series (75). It produced
improvement of symptoms of acromegaly in up to 70% of the
patients, but tumor shrinkage was rare; very high doses
(10–20 mg/d) are generally required, and side effects are
common (76). Variable results have been reported recently
using cabergoline, a selective D2 receptor agonist more po-
tent than bromocriptine (77–79). Disease control is more
likely achieved in patients with mixed prolactin (PRL)/GH-
secreting adenomas than in the pure GH-secreting ones, and
in patients with lower GH and IGF-I levels before treatment
than in those with more aggressive disease (6).
Somatostatin analogs are, at present, the most widely used
drugs to control acromegaly. Octreotide is an octapeptide,
displaying a high affinity for somatostatin receptor subtypes
2 and 5 and a faint affinity for subtype 3, which has been
largely used in acromegaly with excellent results (80). Oct-
reotide given sc at a dose of 100–250 g every 8 h for 6
months reduced GH levels below 5 g/liter in 53% and
normalized IGF-I levels in 68% of 115 patients enrolled in a
multicenter placebo-controlled study (81). A metaanalysis of
466 patients treated worldwide showed that octreotide sup-
pressed GH levels below 2.5 g/liter in 29.2%, normalized
IGF-I levels in 39.9%, and reduced tumor size (20% of
reduction in maximal diameter) in 38.6% of patients; the
GH-lowering effect was related to initial GH values (6). Most
clinical signs and symptoms of acromegaly, such as sweat-
ing, soft tissue swelling, fatigue, and headache, are generally
relieved after the administration of the first doses of oct-
reotide. Twenty percent of patients develop gallbladder ab-
normalities (biliary sediment/sludge, microlithiasis, or gall-
stones), but morbidity is negligible, and treatment with
ursodehoxicolic acid can be performed in those patients with
symptomatic gallstones (80). Lanreotide is another analog,
showing a binding profile comparable to octreotide, and has
a similar efficacy in suppressing GH and IGF-I levels (6, 68).
Depot preparation of lanreotide and octreotide long-acting
repeatable (LAR) have further improved the therapeutic suc-
cess of sc octreotide (68). In particular, we showed tumor
shrinkage, graded from mild to notable, in 80% of 15 newly
diagnosed patients treated for 12 months with octreotide-
LAR, suggesting its potential application as primary therapy
in invasive adenomas (82). Our data have been subsequently
confirmed by the results of a multicenter prospective study
showing tumor shrinkage in all 27 newly diagnosed patients
with acromegaly with median tumor volume reduction of
49% in microadenomas and 43% in macroadenomas (83).
However, because a large variability in tumor shrinkage has
been reported, it is still hard to estimate tumor size response
to slow-release somatostatin analogs. Both depot formula-
tions are well tolerated; the mild-to-moderate side effects
experienced by up to 50% of the patients have short duration
and often subside with treatment continuation (6, 68, 80).
As anticipated, the newest drug for treating acromegaly
bases its efficacy on blocking the activity of the GH-R,
thereby inhibiting the synthesis of IGF-I (53). In a placebo-
controlled study, there was a significant dose-dependent fall
in serum IGF-I in three groups treated with the GH-antag-
onist compared with placebo-treated patients, and 90% of
patients treated with the highest dose (20 mg) achieved nor-
mal IGF-I levels for age (54). In line with IGF-I decrease,
IGFBP-3 similarly decreased, and patients experienced an
improvement of physical well-being and clinical signs. These
results persisted until 24 months (55). Even if data on this
new drug are still scant, the GH-antagonist seems to be well
tolerated, except for rare cases of increased hepatic transam-
inase levels; two of 133 patients had increased tumor mass
(54, 55), one of them being stabilized after a combined treat-
ment with the GH-antagonist plus octreotide (84). Currently,
the use of GH-antagonist is permitted in the United States
and is still experimental in the rest of the world, but the drug
should be available for treatment of acromegaly by the be-
ginning of 2004.
II. The Complications at the Cardiovascular System
A. Epidemiology
GH and IGF-I elicit primary regulatory activities both in
developing heart growth and in maintaining its structure
(21). In the theoretical absence of other cardiac diseases, the
involvement of the heart in acromegaly defines the acrome-
galic cardiomyopathy, which was first described at the end
of the 19th century (85). Although the prevalence of the
acromegalic cardiomyopathy has not been investigated in
detail, its most common feature is considered to be a con-
centric biventricular hypertrophy (21, 86–90). Cardiac walls
are generally thickened, but cardiac chambers are rarely en-
larged due to the relative increase of cardiac myocyte width
for the parallel assembling of new contractile-protein units
(91). Aging and long duration of GH/IGF-I excess are main
determinants of cardiac derangement; results collected in
vivo and postmortem showed a prevalence of cardiac hy-
pertrophy higher than 90% in patients with long disease
duration (92, 93). However, more recent surveys demon-
strated that structural changes of the heart can even occur in
patients shortly exposed to GH hypersecretion (94–96), and
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20% of normotensive patients younger than 30 yr develop
cardiac hypertrophy (96). In particular, we recently reported
that the left ventricular mass index was approximately 30%
higher in 25 acromegalic patients below age 40 yr than in 25
age-matched control subjects (Fig. 3); 60% of the patients had
clear-cut left ventricular hypertrophy (97). Characteristically,
the cardiac hypertrophy of acromegaly occurs in the absence
of hypertension that is present in approximately one third of
patients (see Section II.C) and is further aggravated by hy-
pertension and glucose abnormalities. In our analysis (22),
100% of patients with hypertension and diabetes had cardiac
abnormalities at echocardiography (Fig. 4). The acromegalic
cardiomyopathy develops after three steps: 1) in the early
phase, and thus mainly in young patients with a short disease
duration, there is initial cardiac hypertrophy, high heart rate,
and increased systolic output altogether configuring the hy-
perkinetic syndrome (98); 2) in the middle phase, hypertro-
phy becomes more evident, signs of diastolic dysfunction
appear, and insufficient systolic function on effort can be
documented; and 3) in the end-stage of untreated disease,
cardiac abnormalities may include systolic dysfunction at
rest and heart failure with signs of dilative cardiomyopathy
(21, 99). It should be considered, however, that longer acro-
megaly duration is generally accompanied by an older age,
and it is well known that aging is accompanied by significant
cardiovascular modifications, both structural and functional
(100). In the nonacromegalic population, aging is associated
with a slight degree of left ventricular hypertrophy and de-
crease, even modest, of resting heart rate and early filling
rate, whereas end-diastolic and end-systolic dimensions,
FIG. 3. Effect of age on the left ventricular mass index (LVMi, left) and response of left ejection fraction at peak exercise (LVEF, right) in our
series. Acromegalic patients and controls were grouped according to age [40 yr (n  32), 40–60 yr (n  33), and 60 yr (n  22)]. Data are
derived from our own experience and include data reported in Refs. 97, 191, and 199. *, P 0.001 vs. controls; **, P 0.001 vs. before treatment
that consisted of octreotide-LAR at a dose of 20–40 mg/month.
FIG. 4. Prevalence of left ventricular
hypertrophy, impaired diastolic filling,
and inadequate ejection fraction at rest
in 130 patients with acromegaly stud-
ied at their diagnosis and grouped on
the basis of the absence of hypertension
and glucose tolerance abnormalities,
absence of hypertension and IGT, ab-
sence of hypertension and diabetes mel-
litus, hypertension and glucose toler-
ance abnormalities, hypertension and
IGT, hypertension and diabetes melli-
tus. [From A. Colao et al.: J Clin Endo-
crinol Metab 85:193–199, 2000 (23).
Permission granted by The Endocrine
Society.]
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stroke volume, and ejection fraction are largely unchanged.
It should be noted that in acromegaly the prevalence of left
ventricular hypertrophy is predominant but, besides hyper-
trophy, the majority of the patients at diagnosis have a nor-
mal (55–78%) left ventricular ejection fraction in resting con-
ditions (23).
Rhythm disturbances, such as ectopic beats, paroxysmal
atrial fibrillation, paroxysmal supraventricular tachycardia,
sick sinus syndrome, ventricular tachycardia, and bundle
branch blocks, are also more frequently recorded than in
controls mainly during physical exercise (101, 102). Up to
40% of patients can suffer from conduction disorders, and it
is questioned whether recovery from acromegaly improves
this rate (101). Cardiac valve disease is also underestimated;
Lie and Grossman (93) found mitral and aortic abnormalities
in 19% of their autopsy series. Only a few studies have
reported increased prevalence of mitral and aortic valve re-
gurgitation (103, 104). In a recent study, we demonstrated a
high prevalence of both mitral and aortic valve dysfunction
in patients with active acromegaly (105); in particular, com-
pared with controls, the overall prevalence of valve abnor-
malities was increased both in the 42 active patients (86 vs.
24%; P 0.0001) and in the 22 cured patients (73 vs. 9%; P
0.0001). Cardiac valve abnormalities were associated with
left ventricular hypertrophy both in the patients and in the
controls, whereas among the subjects without left ventricular
hypertrophy, mitral and aortic abnormalities were highly
prevalent in the patients (75% of active and 54% of cured) and
only minimally in the controls (3% of the active and none of
the cured controls) (105). If acromegaly is not controlled,
diastolic heart failure can develop as the most common end-
stage feature of the acromegalic cardiomyopathy; this is typ-
ically seen in patients with hypertensive or valvular heart
disease (both highly frequent in aged acromegalic patients)
as well as in a variety of clinical disorders, especially tachy-
cardia and ischemia, not so frequent in acromegaly (106).
B. Pathogenesis
The mechanisms of GH and IGF-I action on the heart have
been reviewed recently (21, 107). The effects of GH, IGF, and
their binding peptides on the cardiovascular system are both
direct, via endocrine, autocrine, and paracrine mechanisms,
and indirect because they cause increased cardiovascular risk
and hypertension. GH and IGF-I receptors are expressed in
cardiomyocytes (108, 109), and IGF-I mRNA is present in the
epicardium and the coronary vessel of the human fetus (110).
Neonatal rat ventricle tissue preferentially expresses IGF-II
mRNA transcripts and contains both IGF-IR and IGR-IIR
(111), although cardiac IGF-IR expression is partly blunted in
the adult rat (109, 112). Interestingly, IGF-I immunoreactivity
is reportedly increased in the inner layers of the left ventricle
(113), where both tension and wall stress are high, and grad-
ually decreases toward the epicardial surface (114). IGF-I
expression accompanies the development of left ventricular
hypertrophy (113, 115); in rat myocardium, IGF-I mRNA is
increased after pressure overload secondary to banding of
ascending aorta, aorto-caval shunt, myocardial infarction,
experimental renal, or pulmonary hypertension (113, 116–
118). However, the role of IGF-I in heart development during
the prenatal life is still unclear. In fact, newborns of mice
knocked-out for the IGF-I gene show a reduced body size
compared with control littermates, but heart size is generally
unaffected (119). Similarly, when the IGF-I synthesis in the
liver is abolished by the Cre/loxP recombination system, no
negative effect on the postnatal cardiac size is found (34). In
the GH-R knockout mouse, there was no change in heart
weight (120), although GH secretion rate has a prominent
role in the postnatal cardiac development. Hypophysectomy
in rats induces a decreased cardiac expression of IGF-I
mRNA, which can be restored by exogenous GH adminis-
tration (121). GH administration in hypophysectomized rats
with moderate myocardial infarction does not improve ven-
tricular function (122), whereas GH-secreting tumors im-
planted in rats determine cardiac hypertrophy, enhance the
contractile performance, and produce the elongation of the
action potential of cardiac fibers (91, 123). Exogenous GH and
IGF-I administration in normal adult rats induces a hyper-
trophic response of the heart without developing significant
fibrosis (124). Furthermore, IGF-I increases the intracellular
calcium content and enhances the calcium sensitivity of myo-
filaments in cardiomyocytes (125). Cardiomyocyte stimula-
tion induced by GH and IGF-I is associated with a low-
energy conformational status, mediated by myosin pheno-
conversion from the isoform V3 to a low ATPase activity
isoform (126). GH, either directly (127) or via IGF-I, increases
myocardial hypertrophy (127) and increases myocardial con-
tractility in animal models of chronic GH excess (128) and in
cardiomyocytes from neonatal rats (129), likely via an in-
creased calcium responsiveness of myofilaments (130).
C. The acromegalic cardiomyopathy
Although new sophisticated methods are currently avail-
able to study the acromegalic cardiomyopathy, echocardi-
ography still remains the most used method (131). Clear-cut
left ventricular hypertrophy is found in most patients at
diagnosis, overall in those with long disease history (21), and
interstitial fibrosis constitutes the main abnormality at his-
tology (91, 93, 123). Subsequently, gradual impairment of
heart architecture by increased extracellular collagen depo-
sition, myofibrillar derangement, areas of monocyte necrosis,
and lympho-mononuclear infiltration occurs, thus configur-
ing a pattern of myocarditis (92, 93). Increase of apoptosis in
cardiomyocytes and interstitial fibroblasts, inversely corre-
lated to the output rate, was found in biopsied cardiac tissue
obtained during heart catheterization in acromegalic patients
(132). In a survey performed in our department including 200
patients undergoing echocardiography at diagnosis, left ven-
tricular hypertrophy was found in 120 patients (60%); the left
ventricular mass index significantly increased from young
(30 yr) to elderly (60 yr) patients (Fig. 5). Accordingly, the
prevalence of left ventricular hypertrophy was higher in
patients older than 50 yr (74.3%) than in younger patients
(57% in patients aged 31–50 yr and 35% in those aged 30
yr; our unpublished data). As already mentioned, left ven-
tricular hypertrophy is not negligible in young patients with
a presumed short duration of acromegaly, confirming pre-
vious data of other groups (95, 96) as well as from ours (97).
This suggests that cardiac hypertrophy is an early event in
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acromegaly, which worsens proportionately with the dura-
tion of disease activity. It is known that arterial hypertension
is likely the most important factor aggravating cardiac hy-
pertrophy and has higher prevalence in aged patients (see
Section II.E). In another study including a large series of
patients (23), we observed that hypertension significantly
increased the impact of cardiac hypertrophy, therein docu-
mented in 51% of cases. The prevalence of hypertrophy was
higher in hypertensive patients (Fig. 4), and the multistep
regression analysis showed that the diastolic blood pressure
was the best predictive factor of cardiac hypertrophy (23). It
should be mentioned that patients with hypertension and
diabetes had an older age than those with uncomplicated
acromegaly. Because aging in nonacromegalic subjects is
characterized by a slight increase in left ventricular hyper-
trophy (100), it is likely that in acromegaly this phenomenon
is emphasized. It should be stated, however, that it is cur-
rently unknown whether aging has independent negative
effects on the heart in acromegaly, because there are no
controlled studies in the elderly patients population. In our
series, however, patients older than 60 yr had a significantly
higher left ventricular mass than age- and sex-matched con-
trols, who indeed had an increased mass compared with
young controls (Fig. 3). It is also unknown whether there are
gender differences in the prevalence and severity of the ac-
romegalic cardiomyopathy. Gender difference is well known
to occur in GH and IGF-I secretion both in healthy subjects
(133) and in acromegaly (134, 135). Reviewing our experience
in 200 patients with acromegaly, we did not find any dif-
ference in the prevalence of left ventricular hypertrophy
between women (63.6%) and men (58%); similarly, the prev-
alence of hypertension and diabetes was similar in both sexes
(our unpublished data). A minor but relevant complication
that, similar to hypertension and diabetes, may further com-
plicate acromegalic cardiomyopathy is thyrotoxicosis (136),
which appeared to primarily affect systolic function.
Cardiac hypertrophy is associated with functional alter-
ations. The most striking cardiac disorder of early acrome-
galic cardiomyopathy is represented by inadequate filling
capacity. Doppler ultrasonography documented that both
the diastolic filling wave and the early to late mitral and
tricuspid velocity ratio are generally decreased, whereas a
limited elasticity of myocardial fibers causes the elongation
of the isovolumic relaxation time (21, 99). This disorder can
remain asymptomatic for years before clinical and instru-
mental signs of cardiac involvement become overt. In the
presence of diastolic impairment, the incomplete recovery of
an adequate preload can affect systolic parameters during
the physical effort (21, 99). In our cohort, inadequate diastolic
filling (measured as an early to late mitral flow velocity ratio
1) was found in 41.5%, whereas inadequate left ventricular
ejection fraction at rest (50%) was found in 28% of 200 cases
studied by echocardiography. As for the left ventricular hy-
pertrophy, impairment of diastolic and systolic functions is
more evident in older than in younger patients (Fig. 5). Ra-
dionuclide studies have provided a more accurate estimate
of diastolic abnormalities and impaired ejection fraction on
effort, revealing functional alterations in most patients (137).
After excluding patients with hypertension and diabetes, in
a smaller cohort of patients with uncomplicated disease com-
pared with age-matched controls we observed a decline of
the ejection fraction response to physical exercise according
to age (Fig. 6), with abnormal results in 40% of young patients
and 95% of middle-aged patients. In the same cohort, dia-
stolic filling was inversely correlated with the estimated dis-
ease duration (Fig. 7). These findings strongly support the
hypothesis that a long exposure to high GH and IGF-I levels
has detrimental effects on cardiac performance even in the
FIG. 5. Results of the echocardiogra-
phy study performed at diagnosis in 200
patients with acromegaly studied at the
Department of Molecular and Clinical
Endocrinology and Oncology, Univer-
sity “Federico II” of Naples. Data are
shown according with patients’ age di-
vided into decades. The left ventricular
mass index (LVMi, top left) significantly
increases with aging, whereas diastolic
filling, measured as early to late mitral
flow velocity (E/A, top right), and left
ventricular ejection fraction at rest
(LVEF, bottom left) significantly de-
crease with aging. As a consequence,
the prevalence of left ventricular hyper-
trophy (LVH), inadequate diastolic fill-
ing, and systolic performance increases
with aging.
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absence of hypertension and diabetes, the most important
complications of the disease. According to the results of the
Framingham heart study (138), an increase in left ventricular
mass predicts a higher incidence of clinical events, including
death, attributable to cardiovascular disease. The relation-
ship between left ventricular mass and cardiovascular events
persisted after adjustment for age, diastolic blood pressure,
pulse pressure, treatment for hypertension, cigarette smok-
ing, diabetes, obesity, the ratio of total cholesterol to high-
density lipoprotein (HDL) cholesterol, and electrocardio-
graphic evidence of left ventricular hypertrophy (138).
Whether this relationship is also present in the acromegalic
population, which presents a remarkably higher prevalence
of left ventricular hypertrophy than the nonacromegalic one,
is unknown. However, studies of the coronary artery disease
in acromegaly are very scant. Hemodynamics of the coronary
perfusion have not been studied extensively, and thus there
is no general consensus as to the prevalence of coronary
artery disease in acromegaly; it has been reported between
3% and 37% in different series (21). Postmortem and heart
catheterization studies showed a prominent involvement of
small vessels, and the thickening of the intramural vessels
has been described in up to 22% of cases (92, 93, 123). Prox-
imal arteries are generally normal, but they can be either
enlarged and tortuous or, rarely, stenotic (93). Episodes of
angina pectoris are rarely reported, but the presence of
chronic myocardial ischemia cannot be excluded. On the
other hand, systematic evaluation by myocardial perfusion
scintigraphy has never been performed so far; in a previous
study we detected coronary artery disease by myocardial
perfusion in 20% of cases (139). The coexistence of additional
risk factors may accelerate the progression of events leading
to dysfunctional cardiomyopathy. Arterial hypertension, ar-
rhythmias, and metabolic complications (see Sections II, D
and E, and III), as well as common cardiovascular risk factors
such as cigarette smoking, hereditary disorders, and elevated
levels of lipoprotein-a (Lp-a), homocysteine, fibrinogen, and
triglycerides have all been associated with increased cardio-
vascular morbidity (140). Untreated acromegaly is also ex-
posed to elevated levels of triglycerides, apolipoprotein
(Apo) A-I and Apo E, fibrinogen, plasminogen activator in-
hibitor activity, and tissue plasminogen activator (21). The
role of this multifactorial mosaic should be considered to
define the progression of cardiovascular complications and
their potential reversibility in individual patients with
acromegaly.
D. Arrhythmias
Electrocardiography studies and Holter recordings have
documented abnormalities of cardiac rhythm. Supraventric-
ular premature complexes do not seem to occur more fre-
quently in acromegaly than in the normal population (141).
Conversely, ectopic beats, paroxysmal atrial fibrillation, par-
oxysmal supraventricular tachycardia, sick sinus syndrome,
ventricular tachycardia, and bundle branch blocks are fre-
quently recorded in patients with acromegaly, mostly at peak
physical exercise (101, 102). Forty percent of patients suffer
from conduction disorders at the diagnosis of acromegaly.
Both the prevalence and the severity of ventricular arrhyth-
mia were found to be significantly higher in patients com-
pared with controls (101). In particular, complex ventricular
arrhythmias were found in 48% of acromegalic patients as
compared with 12% of controls, and repetitive ventricular
arrhythmias occurred in 31% of patients and 8% of controls
(101). The frequency of ventricular premature complexes
increased with the duration of acromegaly and, interestingly,
the severity of ventricular arrhythmias correlated with left
ventricular mass (101). In one case of sudden death (142),
examination of the conduction tissue at autopsy revealed
slight fibrolipomatosis and dispersion of the atrioventricular
node, the right branch was prematurely intramural with
sclerosis and lipomatosis, and the microscopic examination
supported the hypothesis of electrical instability in the heart.
Additionally, Herrmann et al. (143) investigated ventricular
late potentials in active acromegaly to identify early markers
of cardiac alteration. Late potentials, which are low-ampli-
tude, high-frequency waves in the terminal tract of QRS-
complexes at electrocardiogram (ECG), are considered as
strong predictors of arrhythmic events in patients with pre-
vious myocardial infarction (144). Late potentials were found
in 56% of patients with active acromegaly compared with 6%
of patients with well-controlled acromegaly and none of
controls (143). The detection of late potentials was indepen-
dent of age, gender, disease duration, body mass index, and
FIG. 6. Linear correlation analysis in patients (F) and controls (E)
between age and left ventricular ejection fraction at rest (top) and at
peak exercise (bottom). [From A. Colao et al.: J Clin Endocrinol Metab
84:1518–1523, 1999 (137). Permission granted by The Endocrine So-
ciety.]
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left ventricular hypertrophy measured by echocardiography
(143). Increased prevalence of late potential was confirmed
in another study (145). However, to date no prospective data
are currently available to infer the prognostic value of this
measurement in acromegaly. Using Holter ECG, we have
recently reported ventricular premature beats (50 beats/24
h) in 33.3% of patients (146). Holter ECG analysis can be very
informative before surgery, because severe arrhythmias can
be a sudden cause of death in acromegaly.
E. Hypertension
Arterial hypertension is considered one of the most rele-
vant negative prognostic factors for mortality in acromegaly.
However, both epidemiology and pathophysiological mech-
anisms are far from totally clear. Hypertension is reported to
affect approximately one third of patients with acromegaly,
but only a few studies have estimated the prevalence of
hypertension using the 24-h pressure Holter recording (147–
150), and no control populations were included in these
studies. The only study including a control group (151) re-
vealed an increased prevalence of hypertension only in pa-
tients with familiarity for hypertension. In a survey study of
200 patients with acromegaly studied at diagnosis, we have
found hypertension (based on a diastolic blood pressure 90
mm Hg) in 40%, compared with 8% of controls; there was no
gender difference in the patients or in controls (our unpub-
lished data).
One mechanism likely contributing to inducing hyperten-
sion in acromegaly is represented by the increased plasma
volume (152, 153). The evidence of an increase in the total
exchangeable sodium pool in normotensive (154–157) and
hypertensive acromegalic patients (151) further supports this
hypothesis, because a direct relationship was demonstrated
between total exchangeable sodium and blood pressure val-
ues (156, 157). Whether the sodium exchange pump is also
involved is unclear, because either a reduction (158) or an
increase (159) of its activity has been reported. Plasma vol-
ume and total exchangeable sodium were initially supposed
to follow variations of aldosterone secretion. However, the
levels of aldosterone, and its precursors corticosterone and
11-deoxy-corticosterone as well, were found to be normal in
patients with acromegaly without (152, 157, 160, 161) or with
(151) hypertension. Aldosterone levels were not correlated
with disease activity unless overt heart failure was present
(152). Similarly the aldosterone response to stimuli, such as
posture or saline infusion, gave contradictory responses (152,
160, 162). Both the atrial natriuretic peptide (ANP) and the
renin-angiotensin system have been claimed as potential
causes to explain hypertension in acromegaly without suc-
cess. In fact, basal ANP levels were found to be normal (160),
not correlated with disease activity (152), not increased after
saline infusion (160) or increased as in controls (152). Simi-
larly, basal PRA was normal in most studies (152, 157, 160,
161), not correlated with disease activity (152) or hyperten-
sion (151), and reduced (155, 161) or inappropriately reduced
to hypernatremia (155, 156); the response of the renin activity
to stimuli was also unclear (152, 153, 157, 160, 161). The
adrenergic system has also been investigated, but no clear
evidence for its involvement emerged from different studies.
Plasma epinephrine and/or norepinephrine levels were nor-
mal (157, 163, 164) or increased (165), and urinary cat-
echolamines were also normal (157, 163, 166) or increased
(167). Bondanelli et al. (162) reported that plasma cat-
echolamines were normal but without the physiological cir-
cadian rhythm (Fig. 8) that reappeared after successful sur-
gery (Fig. 8). No difference between patients with
acromegaly and controls was found in catecholamine levels
both basally and after hyperinsulinemic clamp (168). No
change of catecholamine levels was found after bromocrip-
tine or lysuride treatment (164), whereas norepinephrine
levels were reduced in another study (167).
Insulin resistance and diabetes are also likely to play a
relevant role in the onset of hypertension in acromegaly (169,
170). We found significantly higher blood pressure levels in
FIG. 7. Linear correlation analysis between the esti-
mated disease duration and the diastolic filling, mea-
sured as the ratio between the peak filling rate and the
peak ejection rate. [Data were modified from A. Colao et
al.: J Clin Endocrinol Metab 84:1518–1523, 1999 (137).
Permission granted by The Endocrine Society.]
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patients with acromegaly associated with reduced glucose
tolerance or diabetes than in those with normal glucose tol-
erance (23). However, fasting insulin levels were signifi-
cantly correlated with diastolic blood pressure in the control
population but not in the acromegalic population included
in our survey study (Fig. 9). Blood pressure was higher in
subjects with diabetes than in those without diabetes either
in the group with acromegaly or in controls (Table 2). To
note, the age of diabetic patients was higher than that ob-
served in nondiabetic patients, both in acromegaly and con-
trols (Table 2). Glucose tolerance abnormalities indepen-
dently influenced blood pressure measured by 24-h
ambulatory blood pressure monitoring (150), and nondip-
ping profile was associated with insulin resistance in both
normotensive and hypertensive acromegalic patients (149).
Among several mechanisms hypothesized to explain hy-
pertension in acromegaly, the evidence that both cardiac
output and cardiac index are increased, while systemic vas-
cular resistance is reduced (98, 99, 171), has been considered
also. More recent studies, however, suggested that systemic
vascular resistance could be conversely increased in some
vascular districts due to specific morphofunctional alter-
ations. In fact, Chanson et al. (172), measuring direct brachial
artery hemodynamics, showed lower regional blood flow
and increased local resistance in acromegalic patients com-
pared with healthy controls, thus suggesting a heteroge-
neous distribution of cardiac output. Endothelial dysfunc-
tion and/or dysregulation of arterial tone may be responsible
for these abnormalities (see Section II.F). According to
FIG. 8. Plasma norepinephrin (NE) and epinephrin (E) concentrations in blood obtained at 1-h intervals for 24 h from normal subjects and
acromegalic patients before transsphenoidal surgery (A) and from acromegalic patients in remission or active disease after transsphenoidal
surgery (B). [From M. Bondanelli et al.: J Clin Endocrinol Metab 84:2458–2467, 1999 (162). Permission granted by The Endocrine Society.]
FIG. 9. Linear correlation analysis between fasting insulin levels and
diastolic blood pressure in 200 patients with acromegaly () and 100
controls (E) studied at the Department of Molecular and Clinical
Endocrinology and Oncology, University “Federico II” of Naples.
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Folkow’s hypothesis (173), the increased blood pressure in
GH excess could directly originate from an increased thick-
ness of wall resistance vessels. In mice transgenic for the GH
gene (TGHM), Dilley and Schwartz (174) described an in-
crease of wall mass without increase of blood pressure. Hy-
pertensive vessels typically have an increased wall-to-lumen
ratio, and in TGHM mice this was found only for the third
branching order mesenteric vessels and not in thoracic aorta
or carotid artery (174). Moreover, in the mesenteric network,
the number of vessels was lower in TGHM mice than in their
wild-type littermates. A reduction in the capillary density at
the nailfold microcirculation also has been found in patients
with acromegaly (Fig. 10) without any relationship to blood
pressure (175). More recently, a salt-resistant form of hyper-
tension has been described in transgenic mice overexpress-
ing bovine GH (176); an impaired renal excretory capacity
was ruled out by measuring the glomerular filtration rate.
Moreover, in TGHM mice the increased blood pressure was
accompanied by a significant structural narrowing of the
resistance vasculature without changes in vascular reactivity
or endothelial function, allowing the hypothesis that hyper-
tension in these mice is due essentially to an increase of
peripheral vascular resistance (176).
To conclude, the pathogenesis of hypertension in acro-
megaly is still to be elucidated. The coexistence of glucose
abnormalities and insulin resistance increases the probability
of having coexistence of hypertension that can also be due
primarily to increased wall-to-lumen ratio in some vascular
districts. The availability of an animal model of acromegaly
developing hypertension will enable the study of the natural
history of the disease, including abnormal endocrine reaction
to increased plasma expansion, alteration of the renin/aldo-
sterone system as well as ANP release, and negative cardiac
and vascular effects aggravated by electrolytic and metabolic
abnormalities.
F. Atherosclerosis and endothelial dysfunction
Few data are currently available on the vascular involve-
ment in acromegaly. Cardiac output was shown to be het-
erogeneously distributed with lower regional brachial artery
blood flow and increased local resistance (172). The study of
the peripheral microcirculation (Fig. 10) showed a signifi-
cantly lower capillary number and length and a significantly
higher number of tortuous loops and meandering capillaries
in patients with acromegaly than in controls (175). The cap-
illaroscopic alterations were still observed in a smaller group
of patients not bearing diabetes and hypertension (175). In-
crease of the carotid intima-media thickness (IMT) was ob-
served in active as well as cured patients with acromegaly,
but the prevalence of well-defined atherosclerotic plaques
was not higher than in control subjects (177). It should be
noted that in the group of cured acromegalic patients insulin,
cholesterol, and fibrinogen levels were still slightly higher
than in controls (177). The presence of still elevated insulin
levels in patients cured from acromegaly can be the under-
FIG. 10. Capillaroscopy in one control (A) and one patient with acromegaly (B). Note the remarkable meandering of several capillaries. [From
F. Schiavon et al.: J Clin Endocrinol Metab 84:3151–3155, 1999 (175). Permission granted by The Endocrine Society.]
TABLE 2. Effect of diabetes on endocrine, metabolic, and hemodynamic parameters in 200 patients with acromegaly studied at their
diagnosis at the Department of Molecular and Clinical Endocrinology and Oncology of the University “Federico II” of Naples
No glucose alterations Impaired fasting glycemia Impaired glucose tolerance Diabetes mellitus P
No. of subjects 93 26 51 31
Age (yr) 41.7  13.5 49.8  17.3 49.4  12.9 55.3  14.6 0.0001
Median 40 50 50 50
Range 17–76 22–76 26–77 26–76
Estimated disease duration (yr) 10.5  6.7 13.6  7.1 12.3  5.8 15.6  9.8 0.005
Serum GH levels (g/liter) 39.8  25.8 53.6  49.7 38.8  26.8 30.5  21.4 0.035
Serum IGF-I levels (g/liter) 637.1  209.7 776.8  508.1 629.8  208.7 632.6  200.6 0.091
Systolic blood pressure (mm Hg) 130.4  17.6 141.3  19.2 138.2  19.7 144.2  18.2 0.0001
Diastolic blood pressure (mm Hg) 83.8  10.1 89.2  12.4 87.6  11.1 90.6  11.7 0.008
Fasting glucose levels (mg/dl) 83.3  7.1 119.5  7.2 96.9  9.3 150.5  25.3 0.0001
Fasting insulin levels (mU/liter) 22.8  7.3 40.1  15.2 32.8  18.8 51.6  21.3 0.0001
Statistical analysis was performed by ANOVA followed by the Newman-Keuls test. Data are shown as mean SD unless otherwise specified.
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lying factor able to maintain an increased IMT, because in-
sulin levels are known to be directly correlated with IMT
(178). In another series of patients with acromegaly, pro-
spectively studied before and after 6 months of treatment
with lanreotide, an increase of IMT at the level of common
carotid arteries was similarly observed, and 29 of them had
abnormal IMT levels (179). Only a mild increase of carotid
IMT was conversely reported by Kasayama et al. (180); how-
ever, because plasma IGF-I concentration was significantly
higher and the prevalence of hypertension was significantly
lower in patients without than in those with atherosclerotic
changes, the authors concluded that increased concentration
of IGF-I might be involved in the lack of susceptibility to
atherosclerosis in some acromegalic patients (180). We could
not find, however, any correlation between IGF-I levels and
carotid IMT (177, 179).
Laser Doppler flowmetry has also confirmed endothelial
dysfunction at the hand cutaneous circulation. Vascular
smooth cell ability to produce skin vasodilatation was nor-
mal, but endothelium-dependent vasodilatation was im-
paired and sympathetic-mediated vasoconstrictive response
was increased in normotensive acromegalic patients (181).
Very recently, we demonstrated that the increased IMT in
patients with acromegaly mainly depends on concomitant
risk factors, because there was no difference between patients
with active or cured acromegaly and their controls matched
for hypertension, diabetes, or dyslipidemia (182). Interest-
ingly, the endothelium-dependent vasodilatation, measured
at the brachial artery level, was impaired in patients with
active acromegaly more than that expected on the basis of
classical risk factors (Fig. 11); this allowed us to hypothesize
a direct negative effect of GH and IGF-I hypersecretion on
endothelial function (182). Clearly, the existence of other
negative factors, such as glucose intolerance, dyslipidemia,
and smoking habitus, further impairs vascular relaxation.
G. Effect of GH and IGF-I control on cardiovascular disease
A consistent number of investigations (Table 3) have sug-
gested that normalizing GH and IGF-I levels can arrest the
progression of cardiac disorders. This is confirmed by epi-
demiological data (13, 16, 17) showing that the therapeutic
success is associated with a consistent reduction of both
cardiovascular mortality and morbidity in acromegaly. Re-
cently, adenomectomy has been reported to reduce the left
ventricular mass and improve diastolic performance in pa-
tients achieving disease cure (183). A significant improve-
ment of the left ventricular ejection fraction on effort was
similarly documented in patients successfully cured by sur-
gery at the 5-yr postsurgical follow-up (184). Radiotherapy
presents some major limitations, such as partial and/or de-
layed effectiveness and high impact of pituitary deficiency
that prevents further analysis of its beneficial effects on the
cardiovascular risk. In addition, electrocardiograph and
echocardiograph abnormalities have been reported to
worsen during the long-term follow-up in irradiated patients
(185). It should be noted, however, that cure criteria of ac-
romegaly at the end of the 1980s were not strict enough to
accept these conclusions. It is therefore possible that some
patients in the series reported by Rodrigues et al. (102) and
Baldwin et al. (185) were still in active acromegaly at the time
of reevaluation. Improvement of cardiac hypertrophy has
also been reported during long-term treatment with bro-
mocriptine (186), but more extensive investigations are re-
quired to make any conclusive statement. On the other hand,
treatment with somatostatin analogs has been reported to
successfully improve cardiovascular parameters in a wide
number of studies. A prompt reduction of cardiac mass oc-
curs in patients treated with sc octreotide (187, 188), lan-
reotide (189, 190), and octreotide-LAR (191). The effect on the
cardiac mass is even more significant after 6–12 months of
treatment, which is also able to induce improvement of di-
astolic filling (192–196). Diastolic and systolic improvement
is more evident in patients achieving disease control,
whereas those not controlled by therapy had no response
(184) or, even, further impaired their cardiac function (196).
A positive response to octreotide has been reported also in
acromegalic patients suffering from congestive heart failure,
who achieved significant increase of the cardiac output (197).
Similarly, the cardiopulmonary performance, impaired in
acromegalic patients when compared with controls, was
FIG. 11. Boxes showing median values
() and interquartile ranges of flow-
mediated dilatation (FMD) in the study
population. Active, Active acromegal-
ics; Active MC, active acromegalic-
matched controls; Cured, cured acrome-
galics; Cured MC, cured acromegalic-
matched controls. *, Lower than in
healthy subjects (P  0.01); §, lower
than in active MC (P  0.01); #, lower
than in cured (P  0.01); †, lower than
in healthy subjects (P  0.05); ‡ lower
than in cured MC (P  0.05). [From G.
Brevetti et al.: J Clin Endocrinol Metab
87:3174–3179, 2002 (182). Permission
granted by The Endocrine Society.]
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acutely improved by continuous infusion of sc octreotide for
24 h (198). Recovery from left ventricular hypertrophy or
dysfunction appears to depend, however, not only on the
strict biochemical control of acromegaly but also on patients’
age and the duration of GH and IGF-I hypersecretion before
intervention. In a recent study including 22 patients success-
fully controlled for 1 yr by octreotide-LAR, we observed the
disappearance of left ventricular hypertrophy in 100% of
patients aged below 40 yr and in only 50% of those aged
above 40 yr (199). In addition, the left ventricular ejection
fraction response at peak exercise significantly increased
only in younger patients, being restored in 80% of young and
in 50% of middle-aged patients (199). Similar results were
recorded when capacity and duration of exercise were an-
alyzed. Taken together, these observations suggest that ac-
romegalic cardiomyopathy is more likely reversed in
younger patients with short disease duration, whose disease
activity is successfully controlled by 12-month treatment
with octreotide-LAR. Indirectly, these results also indicate
that early diagnosis and effective treatment are mandatory in
acromegaly (199). When cardiac involvement in the early
stage of acromegaly was investigated after 6 months of oc-
treotide-LAR (97), we found that only patients aged below 40
yr and with disease duration no more than 5 yr achieved a
significant decrease of total cholesterol and heart rate, both
at rest and at peak exercise, and a significant increase of
exercise-induced changes of left ventricular ejection fraction
after treatment (97). Although the left ventricular mass index
was significantly reduced in patients with both short (5 yr)
and long (5 yr) disease duration, at the end of treatment it
was still higher than controls; four patients with disease
duration more than 5 yr still showed left ventricular hyper-
trophy (97). Supporting previous findings (99), we found that
young patients with short disease duration had increased
heart rate both at rest and at peak exercise and also increased
exercise-induced changes of the left ventricular ejection frac-
tion (97). Conversely, treatment reduced heart rate and ejec-
tion fraction to normal values (97). Interestingly, young pa-
tients had increased IMT of common carotids at baseline that
significantly reduced after treatment, without any change in
systolic and diastolic peak velocities (97). A less evident
decrease of common carotid IMT was also observed in an-
other series of patients with higher age treated for 6 months
with lanreotide (179). Beneficial effects of somatostatin an-
alog treatment were reported on heart rate (97, 195, 196) of
peculiar relevance when the drug was given preoperatively
(65). This effect can be due not only to the decrease of GH and
IGF-I levels but also to a direct effect of octreotide, which was
shown to have direct effects on the conduction system (200).
Whether subtle alterations of vascular bed or of the renin/
aldosterone system, which cannot be revealed by the com-
monly used detection systems, contribute to changing the
hemodynamic parameters in acromegaly is still unknown. A
remarkable effect of octreotide in reducing the number of
ventricular premature complexes before surgery was also
reported in a 59-yr-old patient (201). In a larger series of
patients included in a recent Italian multicenter study, we
found a significant reduction of mean 24-h heart rate (66.5
11 vs. 71.5 20 beats/min; P 0.05) after lanreotide therapy
(146). Ventricular premature beats (50 beats/24 h) were
found in 33.3% of patients before treatment and in only 16.5%
after treatment (146). Improvement of metabolic alterations
(see Section III) and hypertension (64, 184, 196, 197) have also
been reported, but data are less convincing than those re-
garding recovery from left ventricular hypertrophy, im-
provement of diastolic filling, as well as improvement of
systolic performance (Table 3). Very recently, we had the
opportunity to investigate the effects of the GH-antagonist
on the acromegalic cardiomyopathy. Although the study is
still in progress and data are still unpublished, we observed
that the left ventricular mass was significantly reduced in 15
patients treated with the GH-antagonist at a dose of 10–25
mg/d for 6 months (202). Of notable interest is the evidence
that all but one of these patients had been shown to be
resistant to somatostatin analogs and still showed abnormal
echocardiographic findings (202).
By summarizing the wide number of data available on the
acromegalic cardiomyopathy, we can conclude that it seems
to be a frequent complication of the disease and shows a
peculiar multisymptomatic aspect. If acromegaly is left un-
TABLE 3. Recovery from cardiac disease after treatment of acromegaly
Year Ref. No. ofpatients Treatment Follow-up Methods
Results
LVH Diastolic
function
Systolic
function
Others
1985 185 11 RT 3–17 yr ECG, ECHO n.a. n.a. n.a. 1 Cardiovascular events
1989 192 9 OCT 12 months ECHO 2 n.a. 7 2 HR and BP
1991 193 5 OCT 6 months ECHO 2 1 7 No change in contractility
1992 188 16 OCT 2 months ECHO 2 n.a. 2 Only in patients with hypertrophy
1993 194 11 OCT 6 months ECG, ECHO 2 1 7 7 BP
1994 187 6 OCT 6 months ECG, ECHO 2 1 7 1 Treadmill exercise, 7 BP
1999 196 30 OCT 12 months ERA n.a. 7 1 2 HR only in controlled patients
1999 189 13 LAN 12 months ECHO 2 1 7 7 BP
1999 195 13 LAN 12 months ECHO 2 1 7 7 BP
2000 191 15 OCT-LAR 6 months ECHO, ERA 2 1 7 Only in controlled patients, 2 HR
2001 193 30 Surgery 6 months ECHO 2 1 7 2 BP only in controlled patients
2001 184 18 Surgery/OCT 5 yr ERA n.a. 7 1 Only in controlled patients
2002 97 25 OCT-LAR 6 months ECHO, ERA 2 1 2 2 HR, when disease duration 5 yr
2002 146 19 LAN 6 months ECHO 2 1 7 2 Arrhythmias from 33.3 to 16.5%
2003 199 22 OCT-LAR 12 months ECHO, ERA 2 1 1 Mostly in young patients
n.a., Not assessed; RT, radiotherapy; OCT, octreotide; LAN, lanreotide; ECHO, echocardiogram; ERA, equilibrium radionuclide angiography;
LVH, left ventricular hypertrophy; BP, blood pressure; HR, heart rate; 2, decreased; 1, increased; 7, unchanged.
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treated, cardiomyopathy can lead eventually to diastolic
heart failure. Left ventricular hypertrophy is a characteristic
of the acromegalic heart and is complicated by arrhythmias,
which can be a cause of sudden death of these patients and
should be carefully investigated. Treating acromegaly by
combining surgery, radiotherapy, and pharmacotherapy en-
ables the recovery from cardiomyopathy mostly in young
patients who had had a presumably short exposure to GH
and IGF-I excess. However, a substantial improvement of
both morphological and functional alterations of the cardio-
vascular system has been observed in middle-aged patients,
indicating that cardiovascular complications can be at least
arrested by an adequate control of GH and IGF-I hyperse-
cretion. In contrast, cardiac valve disease does not seem to be
substantially changed by controlling hormone hypersecre-
tion (105), but data on this issue are still scant. Because, as
stated at the beginning of this review, acromegaly develops
insidiously for several years before the diagnosis is made,
more extensive data on prolonged follow-ups are required to
satisfactorily respond to the question of whether the revers-
ibility of cardiovascular complications after biochemical con-
trol of acromegaly is possible and whether this improvement
is paralleled by the normalization of the risk of death for
cardiovascular accidents.
III. The Metabolic Complications
A. Epidemiology
GH has long been known to be associated with changes in
human metabolism. It is well established that GH counter-
acts the effects of insulin on glucose as well as on lipid
metabolism, although it shares anabolic properties on pro-
tein metabolism with insulin. Moreover, GH modulates tis-
sue response to insulin; indeed GH excess may cause insulin
resistance, whereas GH deficiency may increase the sensi-
tivity to insulin (203). GH exerts an overall lipolytic effect,
inducing the hydrolysis of triglycerides to FFA and glycerol.
However, the influence of GH on lipolysis has long been
debated, and either direct or indirect effects on lipolysis have
been described. Conversely, GH has been shown to elicit
some degree of antilipolytic activity in different species de-
pending strictly on other lipolytic factors. Moreover, there is
clear evidence that GH can influence the sensitivity and or
the responsiveness of adipose tissue to agents that influence
lipolysis.
Impaired glucose tolerance (IGT) and overt diabetes mel-
litus are frequently associated with acromegaly (9, 63, 204,
205). Patients with acromegaly are insulin resistant either in
the liver or in the periphery, displaying hyperinsulinemia
and increased glucose turnover in the basal postabsorptive
states (206). The prevalence of diabetes mellitus in acromeg-
aly is unknown but ranges from 19–56% in different series
(207). Alternatively, the most well-known intermediate form
of altered glucose metabolism, referred to as IGT, has been
assessed only recently in three different studies: the preva-
lence was 31% in a study by Biering et al. (208), 46% in the
study by Kasayama et al. (209), and 16% in the analysis by
Kreze et al. (207). Impaired fasting glycemia has recently been
recognized as a second intermediate form of glucose intol-
erance (210). This intermediate disorder of glucose metabo-
lism has not been detected in acromegaly in the only study
where it has been investigated so far (207). Because impaired
fasting glycemia occurs less frequently than IGT in the gen-
eral population, the analysis of this entity appears to require
a larger series of patients and alternative approaches. In fact,
insulin sensitivity is reduced to a similar extent in acrome-
galic patients with normal glucose tolerance and those with
IGT or diabetes, suggesting that a compensatory hyperfunc-
tion of pancreatic -cells might counterbalance the reduced
insulin sensitivity in the patients with normal glucose tol-
erance, but not in those with IGT or diabetes (207). The
presence of impaired fasting glycemia was not assessed in
this latter study. This new category warrants further inves-
tigation because it could predict the risk and/or the pro-
gression of developmental alterations of glucose metabolism
in acromegaly.
As already mentioned, as well as suggested in even earlier
investigations, the prevalence of overt diabetes mellitus in
acromegaly largely differs among studies, likely due to dif-
ferent patient series and ethnicity (211). In the study by
Nabarro (9), the analysis of risk factors promoting the de-
velopment of glucose intolerance revealed that higher GH
levels, higher age, and longer disease duration significantly
predicted the tendency of developing symptomatic diabetes
(9). In the study by Biering et al. (208), aging was the only
variable that significantly predisposed patients to an increase
in the severity of this complication. Results from a study by
Kreze et al. (207), suggested that the development of glucose
intolerance appeared to be associated with a family history
of diabetes and with the concomitant presence of arterial
hypertension. The importance of family history had already
been suggested in previous analyses, although the support-
ing data was quantitatively insufficient. Systemic hyperten-
sion and IGT were also found to correlate independently to
the severity of acromegalic cardiomyopathy in our patients
(23). Compared with patients with uncomplicated acromeg-
aly, those with hypertension but without abnormalities of
glucose tolerance had an increased prevalence of left ven-
tricular hypertrophy associated with impaired systolic and
diastolic function, whereas patients with glucose tolerance
abnormalities lacking hypertension had only an increased
prevalence of impaired diastolic and systolic function (23). In
our survey study, including 200 patients studied at their
diagnosis, we found impaired fasting glycemia in 13%, IGT
in 25.5%, and diabetes in 15.5% (Table 2), giving an overall
prevalence of different alteration of glucose metabolism in
54% of the patients compared with 23% of controls, and in
our series the prevalence was similar in men and women.
Among other variables, the concomitance of hyperpro-
lactinemia and pituitary tumor size are unlikely to predis-
pose acromegalic patients to impairments of glucose metab-
olism. A positive association was found with female gender
when the data of two studies were pooled, although in each
single study the analysis was not significant (9, 207). It should
be emphasized, however, that epidemiological data on the
prevalence of glucose tolerance alterations in acromegaly
should be reviewed after the currently accepted criteria for
the diagnosis and classification of diabetes mellitus (210).
Besides the increased prevalence of glucose abnormalities,
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acromegaly is also associated with abnormalities of lipid
metabolism. Already in the early 1970s, patients with active
acromegaly were shown to have lower cholesterol levels and
higher triglyceride levels than in an age-matched control
population. The incidence of hypercholesterolemia was sim-
ilar to that in the general population, whereas the incidence
of type IV hypertriglyceridemia was almost three times
higher than in controls (212). Serum triglyceride levels were
not related to relative body weight, basal serum GH, or
insulin concentrations, nor did they correlate with glucose
tolerance or with plasma insulin response to oral glucose
load. However, patients with a higher insulin response had
significantly higher serum triglycerides than the remaining
acromegalic population. The endogenous serum triglycer-
ides turnover rate was apparently unaltered, but the in-
creased serum triglyceride levels were associated with an
increase in production rate (212). In a small cohort of patients
with active acromegaly, hyperlipidemia occurred in 63%,
type V hyperlipoproteinemia in 13%, and type III hyperli-
poproteinemia in 6% (213). In these latter cases, the activity
of hepatic triglyceride lipase of lipoprotein lipase (LPL) was
decreased (213). GH stimulates Apo E secretion, and Apo E
as well as Apo A-I concentrations are significantly elevated
in acromegalics (214); a correlation between GH, IGF-I, and
changes in fibrinolysis has been observed in acromegalics,
and disturbances in fibrinolysis may be a major cardiovas-
cular risk factor for these patients. Plasma levels of Lp-a, Apo
A-I, and Apo E are similarly increased, and 30% of patients
have increased plasminogen activator inhibitor activity,
whereas 66% have increased tissue plasminogen activator
concentration levels compared with controls (214). A study
of low-density lipoprotein (LDL) subfraction distribution in
24 patients with active acromegaly showed significantly
higher LDL-III levels when compared with controls, with a
concomitant reduction in the intermediate subfraction
LDL-II (215). In this study, acromegalic patients were found
to have lower hepatic lipase and LPL activities and higher
plasma cholesteryl ester transfer protein (CETP) activity than
controls (215). Univariate analyses showed that both GH and
IGF-I correlated directly with LDL-III and inversely with
LDL-II (215). Maffei et al. (216) reported an abnormal lipid
pattern in 57% of 42 patients compared with 51% of controls;
Lp-a was, however, the only parameter abnormal in 31% of
patients and 7% of controls, whereas both triglyceride and
cholesterol levels were closer to the upper limit of the normal
range compared with controls. The prevalence of an altered
lipoprotein pattern was addressed by Maldonado Castro et
al. (217) in a relatively small series consisting of 20 patients
(12 with active disease and eight cured); the highest Lp-a
levels were observed in patients with active acromegaly,
followed by patients with controlled acromegaly, whose
Lp-a concentrations were still significantly higher than levels
recorded in the normal subjects. There were no differences in
other lipid and lipoprotein values among the groups. This
study suggests that the currently used biochemical criteria
for the cure of acromegaly may not be strict enough to cause
the normalization of all the undesirable metabolic changes
found in this disease. As an indirect consequence, the car-
diovascular risk may persist significantly despite the suc-
cessful treatment of acromegaly (217). Lower levels of HDL
cholesterol and Apo A-I and higher Lp-a concentrations were
confirmed by another study which demonstrated that pa-
tients with acromegaly have smaller and/or more dense LDL
particles compared with controls (218); these alterations
might contribute to the development of atherosclerosis, in-
creasing the cardiovascular risk of these patients. Total cho-
lesterol levels have been reported to be increased, normal, or
even decreased in acromegaly (211, 212, 215). Lp-a, small
dense LPL, and triglycerides were most likely to be increased
(211, 212, 215–218), whereas HDL-cholesterol levels were
unchanged or low (215, 219). Decreased levels of lecithin/
cholesterol acyl transferase, CETP, phospholipid transfer
protein activity levels, plasma cholesterol esterification, and
cholesteryl ester transfer have also recently been reported
compared with controls (220). At multistep regression anal-
ysis, plasma IGF-I was demonstrated to be negatively cor-
related with plasma lecithin/cholesterol acyl transferase,
CETP, and phospholipid transfer protein activity (220). Post-
prandial lipoprotein remnant levels, which are commonly
associated with premature atherosclerosis, have also been
found to be significantly elevated at baseline and in the
postprandial period in acromegalic patients (221). The al-
tered postprandial response of lipoprotein remnant may in-
crease the susceptibility for premature atherosclerosis, as
observed in patients with acromegaly.
Abnormalities of protein metabolism in acromegaly have
not been investigated as deeply as glucose and lipid metab-
olism thus far. GH increases muscle weight and nitrogen
retention; these effects are partially indirect, via hepatic and
locally produced IGF-I, and partially direct. However, most
changes in protein metabolism are derived from the influ-
ence of GH and IGF-I on renal function. Glomerular hyper-
filtration is a characteristic feature of acromegaly; overnight
urinary albumin excretion rate and creatinine clearance are
higher in patients than in controls, suggesting an influence
of GH and IGF-I levels on albuminuria (222). This phenom-
enon is emphasized during submaximal exercise, where in-
creased microalbuminuria is likely to be due to functional
glomerular involvement (223).
B. Pathogenesis
1. Glucose metabolism. The mechanisms responsible for the
GH action on carbohydrate metabolism have been investi-
gated at different levels. Pharmacological doses of GH de-
crease glucose utilization; therefore, GH excess has been
shown to induce insulin resistance by impairing the ability
of insulin to suppress glucose production and stimulate glu-
cose utilization. Numerous authors investigated how GH
and IGF-I modulate insulin actions by altering insulin re-
ceptor binding or postreceptor events. Earlier studies sug-
gested that impairment of glucose metabolism develops only
in the so-called prediabetic patients, such as those with a
decreased insulin response to hyperglycemia and thus un-
able to overcome the diabetogenic effect of GH by compen-
satory hyperinsulinism (224). In fact, the plasma insulin re-
sponse to glucose is notably increased in patients with active
acromegaly and with a normal glucose tolerance. Moreover,
the insulin response to glucose is more pronounced in pa-
tients with highly active acromegaly than in those with mod-
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erately active disease (224). Sonksen et al. (204) confirmed the
presence of hyperinsulinism in a number of patients with
acromegaly, delineating two intermediate stages in the de-
velopment of diabetes in acromegaly: 1) a hyperinsulinemic
stage, characterized by a normal or borderline glucose tol-
erance with a more rapid and higher insulin peak after glu-
cose load, returning to normal later than controls; and 2) a
stage characterized by a delayed insulin response to glucose
in the presence of normal or slightly impaired glucose tol-
erance, which is likely reversible after adequate treatment.
These authors (204) described an additional third stage char-
acterized by a maximal pancreatic response in the fasting
state with no further rise in insulin concentrations after glu-
cose administration, which is likely irreversible after treat-
ment. Therefore, GH excess is likely to induce a state of
insulin resistance, initially manifested as a rise in fasting
insulin concentration and an exaggerated insulin response to
the glucose load. If GH excess remains untreated, fasting
hyperglycemia may develop with a fall in fasting insulin, but
a more dramatic loss of insulin response to the glucose load.
The number of insulin receptors, their affinity, and/or
postreceptor defects may play a role in the development of
glucose metabolism alterations in acromegaly as well. Mug-
geo et al. (225) demonstrated the abnormal binding of insulin
to its receptor on circulating monocytes, which correlated
with the severity of GH excess as well as with abnormal
carbohydrate metabolism and insulin secretion. Moreover, in
patients with euglycemia or hyperglycemia, the total recep-
tor concentration per cell was decreased proportionately to
hyperinsulinemia (226). In diseases involving the GH/IGF-I
axis, the decrease in insulin sensitivity cannot be attributed
exclusively to an alteration of insulin binding, but postre-
ceptor defects must also be considered (227). In acromegaly,
suppression of glucose production was impaired at insulin
concentrations in the physiological but not in the supra-
physiological range, whereas stimulation of glucose utiliza-
tion was decreased at insulin concentrations in both the
physiological and supraphysiological ranges (228). The de-
creased glucose utilization at supraphysiological insulin con-
centrations, together with normal monocyte and erythrocyte
insulin binding, suggests that there is a postreceptor alter-
ation in insulin action in acromegaly (228).
New insight in the pathogenesis of insulin resistance in
acromegaly is derived from the prospective analysis of pa-
tients studied before and after cure. Cure is generally ac-
companied with the remission of diabetes and recovery of the
normal pattern of insulin secretion, although this latter may
be delayed. In fact, in a controlled study, acromegalic pa-
tients with normalized GH levels still had increased insulin
secretion after glucose ingestion, suggesting either a persis-
tently increased pancreatic islet -cell mass or peripheral
insulin resistance (229).
Insulin resistance in chronic GH excess might be accom-
panied by impaired muscle glucose uptake and nonoxidative
glucose metabolism, which are considered early derange-
ments, as observed in patients with normal glucose tolerance
(230). Patients with acromegaly have indeed impaired pe-
ripheral muscle glucose uptake despite high insulin levels.
Increased activity of the hepatic glucose-glucose 6-phosphate
cycle is unlikely to contribute to the hepatic insulin resistance
induced by GH, whereas changes in fatty acid metabolism
may be partially responsible (231). On the other hand, in the
early 1990s it was also demonstrated that lipids constitute the
major fuel substrate in acromegalic patients (232). Subse-
quent data from glucose clamp studies showed definitively
that the striated muscle is the primary site of peripheral
insulin resistance (232). An improvement of the intermediate
metabolism was reported after successful surgery (232). As
already stated (see Section II.E), there is a close correlation
between blood pressure values and plasma insulin levels in
acromegaly. Recent studies have critically clarified that in-
sulin sensitivity is clearly reduced to a similar extent in
acromegalic patients with normal glucose tolerance as well
as in those with IGT or diabetes (209). In patients with normal
glucose tolerance, but not in those with impaired glucose
metabolism, a compensatory hyperactivity of -cells coun-
teracts the reduced insulin sensitivity (209). Recently, two
new actors entered the scene: glucose-dependent insulino-
tropic polypeptide and ghrelin. Hypersecretion of fasting
and postprandial glucose-dependent insulinotropic poly-
peptide was recently found to be involved in determining the
occurrence of hyperinsulinemia in acromegaly (233). More-
over, patients with active acromegaly show low levels of
circulating ghrelin that did not change after the oral glucose
tolerance test (234). This may depend on both GH-induced
insulin resistance and the putative GH/IGF-I negative feed-
back control on ghrelin secretion. Further studies should
investigate the potential role of ghrelin on metabolic path-
ways in acromegaly, because this recently discovered pep-
tide has a wide range of metabolic functions. Insulin resis-
tance in acromegaly involves protein metabolism as well,
because both insulin and GH promote protein accretion. In
fact, acromegalic patients recently have been shown to be
severely insulin resistant for both glucose and protein me-
tabolism (235). Although 6 months after successful surgery
insulin resistance for glucose metabolism is completely re-
versed, a marked antagonism with the insulin effect on pro-
teolysis and on leucine oxidation seems still to persist, dem-
onstrating that the effects of GH on protein metabolism are
not reversed by surgery, at least in the short term (235).
2. Lipid metabolisms. Alterations in lipid profile are more
evident in patients with concomitant abnormalities in glu-
cose metabolism, although the influence of genetic, dietary,
ethnic as well as geographical aspects cannot be ruled out.
Although the underlying mechanism of increased Lp-a con-
centrations in acromegalic patients is still poorly understood,
the positive correlation between GH and Lp-a levels, as well
as the decrease of Lp-a after either medical or surgical treat-
ment, not only indicated a close link between these two
parameters but also suggested that Lp-a synthesis may be
GH-regulated (214, 236). However, it should be considered
that other authors did not find any correlation between Lp-a
and IGF-I (217, 237), suggesting that the GH stimulatory
effect on Lp-a may be independent from IGF-I. Similarly,
findings of increased HDL-cholesterol levels after treatment
of acromegaly may be a consequence of GH decrease (214).
GH excess can directly induce the reduction in LPL activity
in acromegaly; a stimulatory GH effect on liver LDL-receptor
expression has also been proven to be independent of IGF-I
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levels (238, 239). The GH effect is probably displayed in the
catabolism of LDL subfractions, because GH has been re-
ported to induce hepatic LDL receptors, which will selec-
tively lower LDL-II more than LDL-III (240).
Of particular interest is the recent data on LDL physical
characteristics in acromegaly (205), because increased risk of
vascular complications is associated with the presence of
small and/or dense LDL particles in both diabetic and non-
diabetic patients. In acromegaly, both hyperinsulinemia and
reduced postheparin lipase activity, already known to in-
fluence the development of hyperlipidemia in these patients,
are among the factors involved in modifying the LDL phys-
ical properties, which might also be modified by the hepatic
lipase activity that is low in acromegaly (241). Therefore,
small and/or dense LDL particles in acromegalic patients are
likely due to factors other than hepatic lipase. Arosio et al.
(218) found a correlation between Lp-a and GH, but not
IGF-I. This confirms that GH and IGF-I have different, and
probably contrasting, effects on Lp-a (242) and supports a
major role for GH in the physiological regulation of Lp-a
expression. Several abnormalities in HDL lipid composition
in patients with acromegaly are consistent with an impaired
plasma lecithin/cholesterol acyl transferase action and a de-
creased phospholipid transfer protein (220). Decreases in
plasma cholesterol esterification and cholesteryl ester trans-
fer and decreases in plasma phospholipid transfer protein
activity in acromegaly may impair reverse cholesterol trans-
port, thereby contributing to the increased cardiovascular
risk. Finally, what remains to be clarified is the significance
of changes in leptin release in acromegaly that are related to
differences in body fat content and mass as well as insulin
resistance (243). However, leptin in acromegaly does not
seem to be influenced directly by GH or IGF-I secretion,
because the acute effect of somatostatin analogs on leptin
levels differs from the effect of a radical cure after pituitary
surgery (243).
C. Effect of GH and IGF-I control on metabolic
complications
Since the late 1960s, it was already recognized that surgical
removal of GH-secreting pituitary tumors improved both
glucose tolerance and diabetes (204). Successively, with the
development of more accurate methods for assessing insulin
immunoreactivity and glucose measurement, increased in-
sulin secretion after glucose load failed to recover in some
patients despite normalization of GH levels (229). Ongoing
abnormalities were suggested to be due to persistently in-
creased pancreatic islet-cell mass and/or peripheral insulin
resistance (229). However, it should be mentioned that cure
criteria of acromegaly at that time were significantly different
from those currently accepted. When stricter criteria for the
control of the disease were considered, together with more
sophisticated methods for assessing glucose and lipid me-
tabolism, reversibility of metabolic abnormalities was dem-
onstrated in a small series of patients that were surgically
cured (232). Somatostatin analogs significantly improve GH
and IGF-I control, especially in those patients in which sur-
gery was unsuccessful, but they were initially suspected to
aggravate glucose tolerance in acromegaly by suppressing
plasma insulin concentrations (244). Later results, however,
demonstrated that glucose tolerance and insulin resistance
were only modestly altered by octreotide therapy (245). Ad-
ditionally, improvement of insulin resistance by octreotide
may likely counterbalance its inhibitory effect on insulin
secretion (245). During octreotide treatment, the early insulin
response to glucose load is reduced and is followed by a
delayed normal increase. However, due to the concomitant
GH suppression, peripheral insulin resistance is reduced,
and glucose tolerance remains generally normal in most pa-
tients (246). Basically, both of the most widely used soma-
tostatin analogs, octreotide and lanreotide, decrease insulin
resistance in acromegalic patients. Interestingly, octreotide-
LAR seems to be more detrimental to glucose metabolism
than lanreotide SR, despite being more effective in reducing
GH and IGF-I levels (247). The mechanism behind this phe-
nomenon is still unclear. We observed, however, that the
negative effect of somatostatin analogs on insulin levels ap-
pears to be more evident at the beginning of treatment,
whereas glucose tolerance usually improves during long-
term treatment with these drugs (68, 82). The newly discov-
ered GH antagonist pegvisomant proved to be effective in
improving insulin sensitivity and carbohydrate metabolism
in acromegalics, an effect apparently independent of weight
loss (248), and suggesting a potential role for this compound
in the treatment of insulin-resistant states other than acro-
megaly (248).
The first study assessing changes in the altered lipid pro-
file after treatment with octreotide in acromegaly reported a
significant decrease in triglyceride levels despite reducing
insulin levels, probably due to direct GH suppression (249).
Several studies reported on the effectiveness of surgery and
somatostatin analogs in lowering Lp-a levels in acromegaly
(205, 206, 236, 249), but negative findings have also been
described (217). Treatment with octreotide is associated with
a general amelioration of lipid profile without any impact on
small and/or dense LDL particles (218). In our cohort of
patients, lipid profile abnormalities were also generally im-
proved by treatment with somatostatin analogs, in either the
short or the slow-acting formulation (64, 68, 97, 179).
Only limited data are currently available on lipid profile
after GH-antagonist treatment. Very recently, van der Lely et
al. (55) reported the results of a multicenter trial that con-
firmed the normalization of IGF-I levels previously shown.
The majority of cases also showed a decrease of insulin and
glucose levels without any change in cholesterol levels,
which were elevated at study entry, nor were there changes
of triglycerides and urea nitrogen. It should be noted that
although 152 patients were included in the study, only data
from 39 of them were available at the 18-month follow-up
analysis (55). In another study including 48 patients receiving
the GH-antagonist for 18 months, total cholesterol levels
increased as well as the total/HDL-cholesterol ratio and tri-
glyceride levels (250). Lp-a decreased, whereas glucose, in-
sulin, homocysteine, and IL-6 did not change (250). Inter-
estingly, C-reactive protein levels that were low at study
entry significantly increased during treatment (250), leading
the authors to hypothesize a direct GH effect on this cardio-
vascular risk parameter. Parkinson et al. (251) recently con-
firmed that successful treatment with pegvisomant in acro-
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megaly increases low baseline serum total cholesterol and
LDL levels, restoring the distribution of values to that of the
general population and improving insulin resistance as well.
In conclusion, successful control of GH and IGF-I excess
improves glucose and lipid metabolism, although at the be-
ginning of treatment with somatostatin analogs an impair-
ment of insulin secretion leading to further increase of glu-
cose may be observed. Generally, this effect subsides with
treatment continuation, but rarely, mostly in elderly patients,
overt diabetes mellitus may develop, inducing treatment
discontinuation. The effect of treatment of acromegaly on
protein metabolism is largely unknown. As far as the new
therapeutic approach to acromegaly is concerned, i.e., the
GH-antagonist, further data are required to establish its im-
pact on metabolic parameters.
IV. The Complications at the Respiratory System
A. Epidemiology
Respiratory disorders constitute a relevant cause of illness
and impaired physical performance in patients with acro-
megaly, contributing to 25% of all deaths recorded in this
condition, where respiratory mortality appears to be three-
fold higher than in normal subjects (19). The pathophysiol-
ogy and clinic of respiratory disorders occurring in acro-
megaly will be more extensively analyzed in the following
two sections. Patients with acromegaly develop several re-
spiratory alterations, as a consequence of anatomical changes
affecting craniofacial bones and soft tissues, respiratory mu-
cosa/cartilages, lung volumes, rib cage geometry, as well as
activity of respiratory muscles (Table 4). This range of ab-
normalities results in two main respiratory dysfunctions,
namely sleep apnea and impaired respiratory function. Sleep
apnea, the phenomenon of recurrent cessation or decrease of
airflow to the lungs during sleep, is a common cause of
snoring and daytime sleepiness in acromegaly. It may affect
as many as 60% of unselected acromegalic patients and 93%
of patients with suspected sleep apnea (25), the vast majority
of cases being due to anatomical narrowing of the upper
respiratory airways causing obstructive sleep apnea (see Sec-
tions IV.B and IV.C). Impaired respiratory function is an al-
teration less frequently investigated in acromegaly and orig-
inates from multiple alterations involving the bone and
muscle structure of the chest as well as the lung elasticity.
Lung volumes become increased in as much as 81% of men
and 56% of women with acromegaly (252–254), whereas up
to 80% of patients may develop subclinical hypoxemia (255).
The impact of respiratory complications is high in acro-
megaly, and several epidemiology studies published since
the early 1970s have documented an increased respiratory
mortality in this condition. Wright et al. (12) showed that the
rate of respiratory mortality was 3- to 7-fold higher in men
and 3- to 5-fold higher in women with acromegaly aged
45–64 and 65–75 yr, compared with age-matched control
populations of England and Wales. This finding was partly
confirmed by the study of Alexander et al. (8), in which the
death rate associated with respiratory disorders was signif-
icantly increased by 6-fold only in acromegalic men and
nonsignificantly increased by 2-fold in women, whereas Na-
barro (9) showed a faint increase in respiratory mortality
among male patients, i.e., three observed deaths vs. two ex-
pected. Despite the progressive improvement of treatment
procedures and cure rates of acromegaly, enhanced rates of
respiratory mortality have been subsequently recorded in
surveys published in the early 1990s; respiratory disorders
caused 25% of deaths reported in 1993 by Bates et al. (13), and
nearly 12% of those reported in 1998 by Orme et al. (18).
Peculiarly, this latter study showed that respiratory mortal-
ity was 85% higher than expected, independent of aging, an
observation that may thus be suggestive of premature mor-
tality among acromegalic patients. It is worth noting, how-
TABLE 4. Morphological and functional alteration of upper and lower respiratory airways, thoracic cage, and lungs in patients with
acromegaly
Site Pathological findings Clinical disorder
Craniofacial region and upper respiratory tract
Soft tissues and muscles Macroglossia (283)
Swelling/lengthening of the soft palate
(266, 267, 273–275, 277)
Impaired airflow transit
Swelling/collapse of the pharyngeal walls (277) Obstructive sleep apnea
Thickening of true and false vocal cords (275, 278) Nocturnal snoring
Bones Overgrowth of mandible, maxilla and ioid
(266, 267, 273, 277)
Fragmented sleep
Mandible protrusion (266, 267, 273, 277) Daytime somnolence
Dorsocaudal rotation of the mandible (273) Morning sleepiness
Organs Thyroid overgrowth (283, 374, 375) Morning headache
Submandibular salivary gland hyperplasia (276)
Neck/thoracic cage and lower respiratory tract
Soft tissues and muscles Small airway narrowing (253–255)
Derangement of respiratory muscles (286, 287) Impaired airflow transit
Cartilages and bones Enlargement/elongation of vertebral bodies (283) Stiffened rib cage
Thickened intervertebral discs of the neck (283) Impaired breathing movements
Thinned intervertebral discs of the thorax (283) Respiratory muscle impairment
Thoracic spine kyphoscoliosis (283) Short inspiratory time
Elongation and divergence of the ribs (283, 285) Emphysema
Organs Lung overgrowth (253–255, 288) Bronchiectasis
Increased lung volume (253–255)
Increased lung compliance (253–255)
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ever, that environmental/social factors, including smoking
habits and industrialization rates, may have significantly
influenced these results. Intriguingly, surveys conducted in
acromegalic cohorts living in Sweden (10) or New Zealand
(15) failed to record any significant increase in respiratory
mortality.
B. Pathogenesis
Experimentally, the expression and the activity of GH and
IGF-I have been investigated in several respiratory cell types.
Both in rodents and humans, GH and IGF-I exert prolifer-
ative effects on lung and smooth muscle cells through in-
teraction with their cognate receptors. This has been con-
firmed in Northern blot studies revealing the presence of
GH-R mRNA in lung epithelium, smooth muscle cells, and
pneumocytes of rodents (256), whereas the expression of
mRNA transcripts for GH-R has been found subsequently in
human fetal lung tissue by RT-PCR followed by Southern
hybridization assays (257). Despite this observation, how-
ever, immunocytochemical analysis of GH-R failed to detect
protein expression in human fetal lung tissue (258). Also,
activated alveolar macrophages in human airway express
gene transcripts encoding for GH and GH-R, IGF-I and IGF-
IR, and several IGFBPs (259). On lung tissue, GH was shown
to enhance the synthesis of type I collagen fibers and mu-
copolysaccharides (260) and to increase compensatory post-
pneumonectomy lung growth in rats (261). Similar effects
have been subsequently shown for IGFs. In fact, IGF-I and
IGF-II were shown to promote cell proliferation in cultured
rabbit airway smooth muscle cells expressing IGF-IR and
IGF-IIR (262). Inversely, IGF-I treatment was unable to in-
duce the elastogenic response in rat pulmonary fibroblasts,
as evaluated by expression of tropoelastin mRNA and sol-
uble elastin levels (263).
C. The sleep apnea syndrome
Excessive nocturnal snoring and sleep apnea are distur-
bances about which acromegalic patients frequently com-
plain. The first report of daytime sleepiness and obstructive
apnea in patients with acromegaly appeared in 1896 (264,
265). It is now evident that between 20 and 80% of patients
may suffer from sleep apnea (25, 266–268). In their detailed
investigation, Grunstein et al. (25) reported the occurrence of
sleep apnea in 60% of unselected patients and 81% of their
entire series, encompassing patients preselected for sleep
disorders. Weiss et al. (266) documented sleep apnea in 75%
of patients, snoring in 78%, fragmented sleep in 60%, daytime
somnolence in 51%, and morning sleepiness and morning
headache in 16% of cases. Similar figures were reported by
Dostalova et al. (267). As expected, these rates notably out-
number those observed in normal middle-aged men (2–4%
prevalence) and women (1–2% prevalence) (269), where
sleep apnea is a common cause of daytime sleepiness, im-
paired cognitive performance, and road traffic accidents. In
the general population, sleep apnea also has been shown to
predispose to ischemic heart disease, arrhythmias, arterial
hypertension, and cerebrovascular accidents (269), which are
also relevant sequelae of acromegaly. Sleep apnea, consid-
ered to be at least 10 (270) or at least five (271) episodes of
apnea/hypopnea lasting at least 10 sec of every sleep hour,
is classified as either central, due to cessation of respiratory
movements, or obstructive, due to narrowing of upper re-
spiratory airways. A combination of these two conditions
leads to mixed sleep apnea. Central sleep apnea is known to
depend on alterations of the nonbehavioral system control-
ling ventilation, as seen in several neurological and cardio-
vascular disorders. It is characterized by repeated apneic
events occurring during the sleep without associated venti-
latory effort. Grunstein et al. (25) noted that as many as one
third of patients with acromegaly developed central sleep
apnea in association with the obstructive type. This obser-
vation was speculatively related to direct effects on the
breathing center exerted by either high GH/IGF-I levels or
an enhanced somatostatin tone, because somatostatin is able
to reduce animal breathing and decrease chemosensitivity to
hypoxia in humans (25). In addition, acromegalic patients
with central sleep apnea had a greater ventilatory response
to hypercapnic hypoxia, compared with patients with ob-
structive sleep apnea (272). Despite this finding, however,
acromegaly is predominantly associated with obstructive
sleep apnea, a disorder ordinarily caused by anatomical ab-
normalities of the pharynx lumen. Under normal conditions,
the pharyngeal potency depends on the balance between the
negative intraluminal pressure on inspiration and the dilat-
ing activity of muscles acting on the tongue and the soft
palate (i.e., the genioglossus and the palatoglossus muscles)
(269). As shown in Table 4, acromegaly causes several ana-
tomical alterations, which may contribute to impairing the
intrapharyngeal balance during inspiration and thus in-
crease pharynx collapsibility during the sleep. By studying
cephalometric geometry, Dostalova et al. (267) observed that
acromegaly causes mandible protrusion, increases the man-
dibular length, and decreases the angle of sagittal maxillo-
mandibular relations. The facial height of acromegalic pa-
tients is frequently elongated, and the mandible may
undergo dorsocaudal rotation, thus causing a dolichofacial
aspect (269). Compared with nonacromegalic patients suf-
fering from sleep apnea, acromegalic patients with sleep
breathing disorders have a narrower pharyngeal airway both
at the level of the uvula tip and at the mandibular plane (267,
273). There is a similar degree of mandible/maxillary over-
growth and soft palate lengthening between patients with
and without sleep apnea, but the uvular-tip plane is signif-
icantly narrower in those with sleep apnea (267). Other rel-
evant pharyngeal abnormalities include swelling of soft tis-
sues and mucosa hypertrophy. These alterations contribute
to increasing the collapsibility of lateral/posterior hypopha-
ryngeal walls on inspiration, which may then become in-
vaginated into the laryngeal vestibule during sleep apneic
episodes (274). Descriptions also exist of tongue hypertrophy
causing fatal asphyxia (9), voluminous bilateral laryngocele
(271), and increased volume of submandibular salivary
glands (276). Remarkably, studies on static pharyngeal me-
chanics have identified the edge of the soft palate and the
tongue base as the narrowest sites in the passive pharynx
(277), whereas Morewood et al. (278) documented obstruc-
tion of the upper airways in 23% of their patients due to the
thickening of both true and false vocal cords. Like ordinary
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sleep apnea, however, the reduction of upper airway muscle
activity at sleep onset appears to be an initial key event for
the development of apnea in patients with acromegaly, be-
cause disordered breathing does not usually occur during
active contraction of upper airway muscles in the awake state
(277). Several studies have also reviewed the correlation be-
tween the severity of sleep apnea and both disease activity
and GH/IGF-I levels. In a series of 11 patients, Perks et al.
(279) diagnosed sleep apnea in five patients whose GH levels
were significantly higher than in unaffected patients. Simi-
larly, four of 10 acromegalic patients with active disease
studied by Hart et al. (280) had obstructive sleep apnea,
whereas none of 11 patients with inactive disease was af-
fected. In the Grunstein et al. study (25), patients with central
sleep apnea had higher GH and IGF-I levels than did patients
with obstructive apnea. At variance with other reports, these
authors failed to demonstrate any relationship between GH/
IGF-I levels and either the severity or the frequency of ap-
neas, whereas aging and disease duration were positively
associated with the rate of apneic episodes (25). The role
played by gender has been addressed by Pekkarinen et al.
(281) using polysomnography; they reported a higher num-
ber of apneic episodes during non-rapid eye movement sleep
in five of six active men and in none of five women. In the
Weiss et al. study (266), the degree of sleep apnea was pos-
itively associated with male gender (3-fold higher prevalence
compared with women), active disease (82% of active vs. 62%
of inactive patients), and aging. Although the positive cor-
relation between central sleep apnea and activity of acro-
megaly implies that control of disease activity may lead to the
disappearance of central sleep apnea, previous studies re-
ported the persistence of sleep apnea after pituitary surgery,
presumably because of the persistence of obstructive causes.
Pekkarinen et al. (281) recorded reversal of sleep apnea in
only one of five patients treated with pituitary surgery,
whereas Pelttari et al. (282) found persistence of periodic
breathing in 10 of 11 patients previously treated by ad-
enomectomy and/or radiotherapy, nine of whom were in-
active at the time of the study.
D. The respiratory dysfunction
Acromegaly alters the structure, elasticity, and function of
the entire respiratory apparatus (Table 4). Patients with ac-
romegaly develop a barrel chest due to changes in vertebral
and costal morphology. Vertebral bodies become enlarged
and elongated due to periosteal bony apposition, whereas
the intervertebral discs thicken at the cervical and lumbar
levels and become thin in the thoracic region, thus resulting
in development of kyphosis (283, 284). The epiphyses of the
osteochondral junctions fail to close, and the ribs become
elongated and diverged. The costochondral junctions may
even become prominent and enlarged, thus giving a typical
rosary-like aspect (285). These anatomical rearrangements
alter the elastic chest mechanics and markedly impair the
inspiratory muscle activation, which is further aggrieved by
muscle weakness/wasting associated with acromegaly. In
fact, muscle biopsy studies have shown segmental fiber de-
generation, foci of small cell infiltration, thickening of cap-
illary basement membranes, and variable derangement of
type I or type II fibers (286). Both bone and muscle alterations
may deteriorate the contraction of sternal intercostals,
scalene, and diaphragm muscles and thus impair the phys-
iological breathing act. Indirect proof of respiratory muscle
dysfunction originates from the study by Iandelli et al. (287),
showing that most patients with acromegaly achieve sub-
normal respiratory muscle force, during either inspiratory or
expiratory breathing. The inspiratory time is usually shorter
and, consequently, the breathing frequency may increase. As
in several neuromuscular disorders, nonvagal afferent in-
formation originating from either weak respiratory muscles
or stiffened rib cage may act centrally to terminate respira-
tion and accelerate the respiratory pattern. The authors’ ob-
servation of a normal chemoresponsiveness of respiratory
muscles is consistent with the normal role of central factors
and the prevalent effect of reduced muscle force in the setting
of the respiratory responses observed (287). The relevance of
lung volumes and ventilation/perfusion relationship is sim-
ilarly crucial in the pathogenesis of respiratory disorders.
Patients with acromegaly develop increased total lung ca-
pacity. This abnormality was originally observed by chest
radiographs and subsequently confirmed in spirometry and
pletismography studies. Brody et al. (288) found lung volume
to be twice the normal in five of six men with acromegaly,
and suggested that this increase was mostly due to hyper-
trophied interstitial tissue. Total lung capacity is increased in
81% of men and 56% of women, 36% have small airway
narrowing, and 26% have upper airway narrowing (252–
255). Eighty per cent of patients examined by Luboshitzky et
al. (255) had subclinical hypoxemia; partial pressure of ox-
ygen in arterial blood ranged between 58 and 90 mm Hg,
whereas four of five patients subjected to lung perfusion
scans showed defects in perfusion, indicative of ventilation-
perfusion derangement. Increased vital capacity was re-
ported in 34% of patients, upper airflow obstruction in 50%,
and nocturnal hypoxemia in 23% of cases (255).
It has been shown that the increased lung volume is un-
related to hyperinflation or muscle strength. Rather, lung
compliance is generally increased, whereas elastic recoil, dif-
fusing capacity, and diffusing capacity per unit of alveolar
volume are unchanged. Based on these evidences, many
authors have attributed lung overgrowth to an increase in the
size of alveoli (25, 252, 289). In line with these findings,
studies of gas exchange across the alveolar capillary mem-
brane failed to demonstrate ventilation/perfusion mis-
matching in patients with acromegaly. Donnelly et al. (290)
reported values of pulmonary distensibility and diffusing
capacity similar to those observed in control subjects. At
significant variance with previous reports, however, they
observed that the diffusing capacity per unit of alveolar
volume was significantly lower than in controls, and thus
interpreted these results as the consequence of an increased
number of alveoli rather than their overgrowth (290). The
role of disease duration and activity on lung disorders has
been similarly analyzed. Lung volumes and the narrowing of
intrathoracic and extrathoracic airways were correlated with
the duration of acromegaly, and longer disease duration
significantly increased the risk of developing respiratory ab-
normalities (252). Other authors failed to reproduce these
correlations (254, 289).
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For the aforementioned reasons, patients with acromegaly
often achieve an inadequate response to ventilatory and skel-
etal muscle demand on effort. The workload at the cycloer-
gometer is significantly reduced in acromegaly compared
with controls, both at anaerobic threshold and at maximal
exercise (97, 137, 198). Studies of aerobic fitness by self-paced
walk test resulted in significantly higher heart rate and per-
ceived fatigue in patients, whereas maximum oxygen uptake
and ventilation threshold at the maximal exercise were sig-
nificantly lower than the predicted values (291). Despite this
body of evidence, however, the causes leading to respiratory
deaths are still largely unknown. Nabarro (9) documented
kyphoscoliosis in 13 cases, chronic bronchitis and emphy-
sema in five, and bronchiectasis in three other patients out of
a total of 256 cases reviewed. In this series, two patients with
kyphoscoliosis and muscle weakness died from chest infec-
tions. In the largest series currently available, Orme et al. (18)
identified 43 cases of cancer-independent respiratory deaths;
the majority (31 cases) were caused by bronchopneumonia/
pneumonia, which may have been smoking-related, whereas
only a minority (11 cases) were attributable to smoking,
chronic bronchitis, emphysema, and chronic airway obstruc-
tion. Despite these indications, however, more accurate as-
certainment of specific mortality causes still awaits further
clarification.
E. Effect of GH and IGF-I control on respiratory disease
Reports published in the early 1980s postulated that tra-
cheostomy and/or tongue plasty needed to be included in
the treatment plans for sleep apnea in acromegaly (274).
Subsequent studies provided convincing evidence that con-
trol of acromegaly, either by pituitary surgery or somatosta-
tin analogs, improved sleep breathing disorders in acromeg-
aly. The likelihood of developing sleep apnea reportedly
decreases to 25% in the case of posttreatment GH levels of 5
mU/liter or less (2.5 g/liter) (292). As previously men-
tioned, nocturnal breathing abnormalities may paradoxically
persist several years after adenomectomy. Initial studies by
Pekkarinen et al. (281) indicated that only one of five patients
cured by pituitary adenomectomy achieved reversal of sleep
apnea. Based on these findings, the authors hypothesized
that anatomical abnormalities occurring in acromegaly were
irreversible or, alternatively, took a longer follow-up time to
improve significantly. Analysis of their results by modern
cure criteria (20), however, revealed that only two of their
patients achieved a reduction of GH levels into the thera-
peutic range. Pelttari et al. (282) studied the occurrence of
periodic sleep breathing through analysis of body and re-
spiratory movements in 11 patients previously treated by
adenomectomy and/or radiotherapy, nine of whom were
inactive at the time of the study. The authors found that
periodic breathing persisted in 10 of their 11 acromegalic
patients (282). Part of the occurrence of sleeping disturbances
was explained by age and body mass index, but not by
gender or by the duration of disease activity/inactivity (282).
The introduction of somatostatin analogs in the clinical prac-
tice dramatically influenced the cure rate of sleep apnea.
Chanson et al. (293) reported the significant improvement of
sleep apnea in three patients treated with sc octreotide. Grun-
stein et al. (25) showed that octreotide treatment decreased
the frequency of apneic and hypopneic episodes by 50% of
baseline values, regardless of whether apnea was central or
obstructive. Of note, these authors documented that patients
with mixed or central sleep apnea achieved the predominant
improvement of the central component of sleep breathing
control. In the study by Ip et al. (268), the severity of ob-
structive apneas was significantly improved by octreotide-
LAR treatment, whereas mixed and/or central sleep apnea
was only modestly changed. In the case of persisting sleep
breathing disorders, the use of continuous positive airway
pressure devices should be recommended to prevent the
long-term cardiovascular consequences of sleep apnea. GH
and IGF-I suppression is also expected to produce similar
beneficial effects on other ventilatory dysfunctions. Lung
volumes and lung distensibility decrease after 3–11 months
of octreotide treatment, whereas diffusion capacity remains
unaltered (289). The change in lung elastic properties after
therapy seems to suggest either changes in surface forces or
increases in the strength of tissues tethering. Thus, changes
in elasticity are reflected by a significantly improved re-
sponse to physical exercise. Giustina et al. (198) observed that
both workload and oxygen consumption at anaerobic thresh-
old increased significantly after octreotide treatment, which
abrogated the difference in exercise capacity recorded at
baseline between acromegalics and controls. A 6-month
treatment with octreotide-LAR did not determine a signifi-
cant increase in the maximal oxygen uptake during a pro-
gressive treadmill test, but patients achieved an increase in
ventilation threshold and in vigor score, as well as a decrease
in perceived fatigue (291).
From the analysis of the above-mentioned studies, respi-
ratory disorders of acromegaly appear to be complex in both
their origin and development. The hypertrophic action of GH
and IGF-I causes structural changes at the level of the upper
as well as the lower airways. Thus, acromegaly leads poten-
tially to several types of ventilatory dysfunction. In upper
airways, remodeling of bones and soft tissues results in the
impairment of the normal pharyngeal patency during sleep
and is key to the onset of obstructive sleep apnea, the prom-
inent type of sleep breathing disorder in acromegaly. Sleep
apnea may affect as much as around 80% of patients and is
apparently more frequent and severe in case of persistently
active disease, elevated GH/IGF-I levels, and male gender.
In up to one third of patients, obstructive sleep apnea can
coexist with the central type likely due to concomitant neu-
ronal stimuli to the respiratory center mediated by the so-
matostatin tone and triggered by an altered sensitivity
threshold to carbon dioxide. Successful treatment of acro-
megaly dramatically improves sleep breathing disorders.
However, the persistence of sleep apnea after surgical cure
of acromegaly may be attributable to an irreversible process
of remodeling of upper airways and should prompt the use
of continuous positive airway pressure devices to prevent
further cardiovascular complications associated with sleep
apnea. In the lungs, the proliferation of pneumocytes and
smooth muscle cells is reflected in the overgrowth of pul-
monary epithelium and thickening of interstitial tissue. This
alteration decreases pulmonary elasticity, whereas lung vol-
umes are increased due to alveoli overgrowth. Clinically, this
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process leads to respiratory dysfunction; the ventilatory re-
sponse on effort is frequently inadequate in the face of a
greater effort as well as the sense of physical exhaustion.
Ventilatory dysfunctions are well correlated with both the
activity and the duration of acromegaly, so that successful
therapy of acromegaly improves significantly the ventilatory
response to effort and the personal sense of weakness. From
the studies reviewed, some questions remain: 1) can suc-
cessful treatment of acromegaly also be reflected in a sig-
nificant improvement of respiratory failure; 2) can respira-
tory dysfunctions consistently contribute to the impact/
progression of cardiovascular complications in acromegaly;
and 3) should researchers look into more specific causes to
explain the enhanced respiratory mortality seen in this con-
dition? Additional investigations are required to fully an-
swer these questions.
V. The Neoplastic Complications
A. Epidemiology
Over the years, epidemiology studies have provided in-
creasingly debated evidence that acromegaly may enhance
the neoplastic risk, and that cancers constitute the third lead-
ing cause of mortality in this condition (8–10, 12–18). The
recently identified relationship between the IGF system and
human cancers has further persuaded many researchers that
neoplasms of acromegaly may constitute an informative
model to legitimize this link. From a teleological point of
view, understanding of the GH/IGF-I role in tumorigenesis
may depend upon reconciling this association with the neo-
plastic phenomena of acromegaly.
The first study exploring the cancer risk in acromegaly was
performed in 1956 by Mustacchi and Shimkin (294) on 223
patients referred to 16 cooperating institutions, yielding
2981.5 person-years at risk. These authors found five patients
with malignancy among 128 men, three of whom had de-
veloped lung carcinomas, and eight cancers among 95
women, two of whom had breast cancer and two had en-
dometrial adenocarcinoma. No colon cancer was recorded,
although a man with leukemia and a woman with sphenoi-
dal angiosarcoma had received pituitary irradiation 15–20 yr
earlier. Compared with the incidence rates recorded in North
American metropolitan areas, they reported a nonsignificant
increase in standardized incidence ratio (SIR) by 1.3 in the
group as a whole (294) (Table 5). Data subsequently pub-
lished by other groups added strength to the argument that
acromegaly may increase both the cancer risk and cancer-
related deaths. In 1982, Klein et al. (295) studied a group of
44 patients to explore the possible association between colon
tumors and skin tags, an occurrence previously noted in the
normal population. They reported four cases of colon ade-
nocarcinoma among 26 acromegalic patients reviewed ret-
rospectively, with no cancer among 17 patients consecutively
studied by colonoscopy. Although the observed rates were
not compared with those obtained in a control population,
the authors speculated that acromegaly increased remark-
ably the risk of colon tumors. Two subsequent studies by
Ituarte et al. (296) and Pines et al. (297) drew similar conclu-
sions. The first investigation documented three cases of colon
cancer among 12 patients, yielding a prevalence of 25% in the
group as a whole and a 3-fold greater risk of colon cancer
than in age-matched controls (296). In the second study on
48 patients, malignancies occurred in seven patients who all
turned out to be Ashkenazic Jews, five of whom had gas-
trointestinal cancers and two had breast adenocarcinoma
(297). Comparison with expected rates derived from age-
sex-ethnic cancer rates yielded a SIR of 4.6 for gastrointestinal
cancers and 3.5 for breast adenocarcinoma (297). In his per-
sonal series, Nabarro (9) reported evidence of malignancies
in 26 of 256 cases, of whom nine were men and 17 were
women. Cancer incidence rates were similar between men
with acromegaly and men from the general population,
whereas acromegalic women had 87% greater prevalence of
cancer than the control population, mainly due to a greater
prevalence of breast cancer (11 observed vs. 2.6 expected) (9).
In 1991, Barzilay et al. (298) examined 120 clinical records of
acromegalic patients; from an analysis of 87 of these charts,
the authors found seven cases of cancer, which yielded a total
standardized incidence rate of 2.45 compared with sex- and
age-adjusted rates. Taken separately, the incidence rate in
women with acromegaly was twice as high as in men (3.5 vs.
1.7). The existence of a causal link between acromegaly and
cancer became even more suggestive after the publication of
a 16-yr follow-up study by Ron et al. (299), who drew records
on 1,041 acromegalic males hospitalized between 1969 and
1985 in United States Veterans Affairs (VA) hospitals, doc-
umenting a total of 116 cases of cancers. These included 27
digestive, 22 respiratory, and 15 genitourinary malignancies,
as well as 27 cases of pituitary cancers. After a comparison
with rates obtained from 3.7 million first admissions to VA
hospitals among white and Afro-American nonacromegalic
patients, acromegalic patients showed a 3-fold greater inci-
dence of both esophageal and colon cancers and a 2.5-fold
higher rate of gastric cancers. The overall standard incidence
ratio calculated for cancers was 1.6 (299). Although remark-
able, these latter results have raised a few criticisms: 1) in-
clusion of 27 cases of pituitary tumors may have originated
from miscoded diagnoses of pituitary adenoma; 2) the prev-
alence of acromegaly emerging from the study outnumbers
that observed in the general population (1 in 4000 vs. 4–6 per
million population) (8); 3) because acromegaly is equally
distributed between genders, results obtained in gender-
restricted populations should be interpreted carefully; 4) in-
clusion of nonacromegalic hospital patients as control pop-
ulation may have led to ascertainment bias (19); and 5)
analysis of databases collected in different centers may mask
significant differences in management practice. Between
then and 1998, two other studies have been published. The
study by Rajasoorya et al. (15) analyzed the clinical deter-
minants of acromegaly outcome from the medical records of
151 patients, followed up during a 26-yr period. These au-
thors documented five cases of malignancies in their series,
which caused overall 9% of the deaths recorded (15). Tumors
were highly variable with regard to tumor type and gender
distribution. A subsequent study by Cheung and Boyages
(300) recorded seven malignant events in 50 patients; five
cancers were diagnosed in women and contributed to a 4.3-
fold higher cancer risk in this subgroup. Although breast and
kidney cancers predominated in this series (two cases each),
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two other subjects developed dual malignancies (300). A
deeper insight into this alleged acromegaly-cancer network
has been provided by the key study published by Orme et al.
(18), who investigated the incidence and mortality for cancer
in a cohort of 1,239 patients, yielding 16,778 person-years at
risk. Besides the study cohort, other strengths of this inves-
tigation resided in the exclusion of all malignancies predi-
agnosed with regard to the diagnosis of acromegaly and the
cross-examination of reliable national cancer registers. The
most striking finding of this study was the lack of difference
in cancer incidence between acromegalic patients and the
normal population (79 vs. 104 malignancies, respectively).
Nevertheless, analysis of SIRs in acromegalic patients re-
vealed a slight increase in colon cancers (SIR, 1.68) and a
lower incidence of bronchial neoplasms (SIR, 0.33). Accord-
ingly, this study partly confirmed previous reports of a
higher incidence of colon cancers and a lower incidence of
rectum and bronchial neoplasms (299), but it failed to record
any significant increase in breast cancer incidence (9). One
drawback emerging from the Orme et al. study (18) is the lack
of a gender-related analysis, which would serve for com-
parative purposes with the prevalence rates reported in the
other large study by Ron et al. (299). However, if we
assume that acromegalic men constituted approximately one
half of Orme’s population, this study showed a lower
prevalence of colon and, significantly, of bronchial cancers
and a slight increase in the number of rectum cancers. In a
successive study, Popovic et al. (301) observed a 3.4-fold
higher rate of cancer incidence in patients with acromegaly,
but the conclusions drawn by this study have been ques-
tioned (302).
On the other hand, mortality studies have shown that
15–24.5% of deaths in acromegaly are related to cancer-
related complications. In the study by Wright et al. (12)
performed on 194 patients living in the Newcastle region,
18% of all deaths were caused by malignancies. Lung and
bowel cancers accounted for almost 70% of all neoplasms,
whereas no death was attributable to breast cancer despite
a significantly higher cancer mortality in women more
than 65 yr of age (12). A successive study performed in the
same geographical area by Alexander et al. (8) documented
that cancers caused 15.5% of all deaths in acromegaly,
cancer mortality being 4.6-fold higher in acromegalic men
than in the normal male population. Other studies re-
ported that malignant events caused 23% (9), 24.5% (10),
and 9% (300) of all deaths recorded in acromegaly and that
the risk of breast tumors was significantly increased (9, 10,
300). Remarkably, no significant enhancement of cancer
mortality was found by Orme et al. (18) in the largest
cohort of patients with acromegaly (83 deaths vs. 72 ex-
pected), although the death rate from colon cancer out-
numbered significantly that recorded in the normal pop-
ulation (13 observed deaths vs. five expected). The
standard mortality rate associated with cancer was in-
creased in the case of posttreatment levels of GH above 10
g/liter (standard mortality rate, 1.81; P  0.05 at 2 test),
but the occurrence of cancer was unrelated to either dis-
ease duration or age at the diagnosis of acromegaly (18).
B. Pathogenesis
The effect of GH and IGF-I on different cell systems has
been discussed in more detail in Section I.C. The first evidence
linking the GH/IGF system to cancer originates from exper-
imental in vitro and in vivo studies. Although the effects
produced by impure extracts of GH should be viewed with
caution due to the potential action of natural contaminants,
Moon et al. (303) recognized in 1950 that chronic high-dose
treatment with extracted GH caused the development of
tumors in lungs, adrenals, ovaries, and breast in female rats.
Administration of bovine GH to Balb/c mice also induced
lymphopoietic tumors, whereas hypophysectomy was found
to modulate the growth of rat liver tumors induced by ben-
zenic compounds and to decrease the growth of breast can-
cers xenografted in mice (304, 305). The role of GH in animal
tumorigenesis was further confirmed in studies in which
transgenic mice expressing human GH developed mammary
tumors (306), although transgene expression of bovine GH
did not appear to be carcinogenetic (307). GH was then found
to stimulate the proliferation of several cancer cell lines in
vitro, including human leukemic lymphocytes and murine
erythroleukemic cells (308). Evidence for GH synthesis in a
number of extrapituitary organs, including the lateral hypo-
thalamus, lymphocytes, thymocytes, neutrophils, the pla-
centa, and both normal and neoplastic mammary tissues,
suggests that GH may have local paracrine/autocrine effects
independent of or additional to endocrine-mediated IGF-I
action (27). In mammary carcinoma cell lines, autocrine GH
functions as a direct proliferative stimulus and decreases
apoptotic activity, with marked synergism with trophic
agents such as IGF-I (309). In prostate cancer cell lines, GH
stimulation increases the rate of cell proliferation, and the
coexpression of both pituitary and placental GH as well as
GH-R mRNA isoforms has been shown in ALVA41, PC3,
DU145, and LNCaP prostate cancer cells, where it can enable
an autocrine-paracrine pathway to stimulate prostate growth
(310). All of the effects of autocrine GH are mediated by
GH-R. GH-R and its signal transductional mechanisms stim-
ulate several genes involved with tumorigenesis, such as
c-myc mRNA expression in liver and kidney (311). Never-
theless, the significance of GH-R activation in experimental
animal models of tumorigenesis remains largely unknown.
Unlike GH, the IGF system modulates the tumorigenic
process at different levels. Most human tumors develop by
a multistep process in which cells acquire growth advantage
by genetic damage, involving an accumulation of mutations.
Gene mutations are usually prevented by host defense mech-
anisms including apoptosis, but several survival factors,
such as IGF-I, may override these internal signals (312). Once
quiescent cells are made competent, stimulation with IGF-I
alone is sufficient to complete the cell cycle, promote cell
proliferation, and arrest apoptosis, both in normal and cancer
cell lines (48, 313). The efficiency of IGF-I stimulation re-
quires an adequate density and functionality of the IGF-IR on
the cell surface, and this prerequisite is also essential for the
IGF-I-mediated proliferation of cells previously transformed
by viral, cellular, and/or chemical oncogenes (48). IGF-I/
IGF-IR involvement in cancer cell proliferation has been
demonstrated in experiments where knockout of IGF-IR
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gene, either by antisense oligodeoxynucleotides, dominant
negative mutants, or triple-helix formation, was capable of
decreasing cell proliferation and increasing apoptosis. The
IGF-I/IGF-IR system appears to further influence cancer pro-
gression by promoting adhesion and migration of cells, as
well as angiogenesis within tumoral tissues and in the sur-
rounding areas (48, 314). Conversely, activation of tumor
suppressor genes, such as p53, BRCA-1, or WT-1, results in
a reduction of IGF-IR gene transcription and, hence, of cell
proliferation (48). In vitro, IGF-I does not seem to promote
cellular transformation, rather it stimulates proliferation of
transformed cell clones and the growth of preexisting tumor
tissues. These effects have been confirmed in studies on
liver-specific IGF-I-deficient mice, in which chronic IGF-I
treatment was able to promote growth and metastatic pro-
liferation of colon adenocarcinomas transplanted on the cae-
cum surface of the animals (315). In addition to its endocrine
functions, IGF-I is widely synthesized locally and exerts au-
tocrine/paracrine effects in a number of tissues and cell
systems. Modulation of IGF-I gene transcription, usage of
either of the two IGF-I promoters, alternative RNA splicing,
and changes in RNA stability allow IGF-I gene expression to
be cell- or tissue-specific, ontogeny-determined, or regulated
by several factors (for review, see Refs. 49 and 316). Regu-
lation of cancer growth through an IGF-I/IGF-IR-mediated
autocrine/paracrine loop emerges from the demonstration
of IGF-IR mRNA expression in colon carcinoma samples,
which is significantly more abundant than IGF-I mRNA ex-
pression (317), and predominates in samples from colon tu-
mor vs. the adjacent normal mucosa, a circumstance that is
suggestive of paracrine and autocrine modulation of tumor
growth (318). In breast cancer, IGF-I is expressed in the
stromal cells and very rarely in the breast epithelium, as
determined by in situ hybridization, whereas IGF-IR has been
found on the surface of malignant breast epithelial cells, an
event that suggests the existence of a paracrine interaction
(for review, see Ref. 319). More recently, increasing attention
has been paid to the biological activity of several IGFBPs,
independently of their binding to IGF-I and/or IGF-II (44).
IGFBP-3 has been extensively shown to promote apoptosis
and arrest the proliferation of numerous tumoral cell lines,
a process that involves intracellular modulation of cyclins
and caspases (320). Initial studies demonstrated that mouse
IGFBP-3 could inhibit the fibroblast growth factor-stimu-
lated proliferation of mouse and chick embryo fibroblasts
(321), whereas exogenous IGFBP-3 addition to HS578T hu-
man breast cancer cells inhibited proliferation, indepen-
dently of IGF-I (322). In other investigations, transfection of
IGFBP-3 cDNA in mouse embryo fibroblasts previously dis-
rupted for the IGF-IR gene inhibited cell growth and pro-
moted apoptosis (323, 324). Furthermore, IGFBP-3 mediates
the antiproliferative activity of TGF-, retinoic acid, vitamin
D, TNF-, tamoxifen, and histone deacetylase inhibitors
(320). The biological activity of IGFBP-3 seems to be medi-
ated by specific receptors present on the cell surface, al-
though nuclear translocation mechanisms have been docu-
mented also.
The second clue relating the GH/IGF system to cancer
originates from clinical studies performed in the normal pop-
ulation. In humans, it has been hypothesized that the pattern
of IGF-I and IGFBP-3 secretion may predict cancer risk dur-
ing the lifetime. IGF-I levels are significantly higher in
women diagnosed with breast cancer (325) and in men har-
boring prostate tumors (326), compared with their normal
counterparts. An 18-yr follow-up study found a positive
association between the risk of developing malignant tumors
and GH levels measured during an oral glucose tolerance test
performed at the baseline visit (327), whereas an even tighter
association emerged in large nested case-control studies be-
tween serum IGF-I levels and the risk of prostate, breast, and
colon cancers (50–52). In a survey on 152 cases of prostate
cancers, among nearly 15,000 men subjected to blood sam-
pling for an average of 7 yr before diagnosis, Chan et al. (50)
provided evidence of a 2.4-fold greater cancer risk associated
with IGF-I levels in the upper quartile of the normal range,
compared with patients whose IGF-I values were in the
lower quartile. By inclusion of IGFBP-3 levels, the relative
cancer risk lifted up to 4.3 and was nearly eight times above
normal in men older than 60 yr. A similar study was con-
ducted by Hankinson et al. (51) reporting that the relative risk
of breast cancer in premenopausal women with IGF-I levels
in the upper tertile of the normal range was 2.3 times higher
than in patients with IGF-I in the lower tertile. In women
below age 50 yr, the highest IGF-I tertile was associated with
an increase in breast cancer risk to 4.6 and, after inclusion of
IGFBP-3 levels in the multivariate analysis, to 7.3 (51). Ma et
al. (52) analyzed IGF-I and IGFBP-3 levels in 193 men diag-
nosed with colorectal cancer over a 12-yr follow-up, and
reported that the relative risk in men having IGF-I levels in
the top quintile was 2.5 times greater than in those whose
IGF-I was at the bottom quintile. Inversely, the relative risk
calculated by IGFBP-3 quintiles was 0.28 for top vs. bottom
quintile. In the Nurses’ Health Study, IGF-I levels did not
predict colon cancer risk unless a combination of high IGF-I
and low IGFBP-3 tertiles was used; patients stratified by the
highest IGF-I and the lowest IGFBP-3 had an increased risk
of colon tumors (328). However, the relationship between
IGF-I and cancer has been recently questioned (329).
The third corollary linking the GH/IGF system to human
cancers arises from the demonstration that GHRH-antago-
nists, GH-antagonist, and somatostatin analogs elicit anti-
neoplastic activity by altering the GH/IGF-I axis at the pi-
tuitary level or by inhibiting autocrine/paracrine activity of
GHRH, GH, and IGFs. Ablative hypophysectomy has long
been shown to reduce the neoplastic progression of dissem-
inated breast and prostate cancers (330). Splicing variants of
GHRH receptors have been found in many cancer cell lines,
and GHRH-antagonists have proven to be able to inhibit
tumor growth in mice xenografted with colorectal, prostate,
breast, and lung cancers (331). Other studies have demon-
strated that somatostatin analogs powerfully suppress tumor
growth in experimental models of pancreatic, prostate, colo-
rectal, breast, and lung carcinoma and elicit marked anti-
neoplastic effects in several types of neuroendocrine tumors;
however, their clinical efficacy in cases of prostate, breast,
and lung cancers is largely disappointing (332, 333). Prelim-
inary findings have indicated that the GH-antagonist de-
creased proliferation, stimulated apoptosis, and reduced
metastatic spreading of MCF-7 breast cancer cells (309).
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C. The gastrointestinal tract
Digestive tumors constitute the most frequent malignan-
cies recorded in acromegaly (Table 5). Experimental studies
have demonstrated that both normal and tumoral colorectal
cell lines express large amounts of IGF-IR, and IGF-I induces
the proliferation and antiapoptotic activity in colorectal can-
cer cells lines (330, 334). The role of serum IGF-I levels in
stimulating tumor growth and metastasis has been further
confirmed in mice carrying liver-specific deficiency of IGF-I,
where both the growth and the metastatic spreading of ad-
enocarcinomas transplanted on the caecum surface were sig-
nificantly increased by a 6-wk ip treatment with IGF-I (315).
In patients with acromegaly, the length of the colon and
sigma is generally greater than in controls, and epithelial
cells of sigmoid crypts present an enhanced pattern of pro-
liferation, which is positively correlated with circulating
IGF-I levels (335, 336). This finding is consistent with the
observation of a decreased apoptotic activity, independent of
Bcl-2 and Bcl-xL proapoptotic proteins (337). It can thus be
speculated that GH/IGF-I excess in acromegaly increases
epithelial cell proliferation and decreases the apoptotic rate,
which then may predispose to a greater accumulation of
genetic defects leading to colon cancer. Many researchers
have intriguingly claimed that one mechanism compensat-
ing for these growth-promoting effects of IGF-I on colon
mucosa may depend upon the concomitant increase in
IGFBP-3 levels, because IGFBP-3 has shown intrinsic anti-
proliferative effects in vitro and its serum levels are nega-
tively correlated with cancer risk (50–52). IGFBP-3 may ei-
ther promote apoptosis through specific receptors or bind
IGF-I in small binary aggregates, thus inhibiting IGF-I ac-
tivity. However, this unresolved issue awaits further clari-
fication. Several other humoral and mechanical factors may
play a crucial role in modulating colon cell proliferation in
acromegaly. Abnormalities in lymphocyte subset pattern,
consistent with a decrease in the number of B lymphocytes
and Natural Killers and an increase in T lymphocytes, have
been described by our group in the colon mucosa of acro-
megalic patients and appeared to be correlated with disease
activity (338). The decrease in helper-inducer lymphocytes
may imply an impairment of local Ig pattern and, hence, of
immune surveillance mechanisms in the colon mucosa. An-
other potential tumor-promoting mechanism resides in the
pattern of bile acid secretion. Unconjugated deoxycolic acids
are able to stimulate the transformation and proliferation of
colorectal cells in vitro, and it has been shown that in the
general population subjects with higher levels of serum and
intracolonic unconjugated deoxycolic acids are at increased
risk of developing colorectal cancer (339). Patients with ac-
romegaly harbor increased serum and intracolonic levels of
secondary bile acids, especially if affected with colorectal
cancer, and the coexistence of this event with a greater colon/
sigmoid loop length and an increased colonic transit has been
suggested to enhance the susceptibility to the development
of colon tumors in acromegaly (340, 341).
The issue of whether acromegaly enhances the risk of
colorectal cancer has attracted great attention, thus generat-
ing a heated debate. Cancers arising in the digestive tract
constitute nearly 27% of all tumors developing in acromeg-
aly, 18% of them being due to colorectal carcinomas (Table
5). The relative importance of esophageal and gastric cancers
has been delineated in the study by Pines et al. (297) reporting
a 7-fold higher risk of gastric cancer in their patient popu-
lation. Upper digestive cancers constituted 60% of all gas-
trointestinal malignancies reported by Ron et al. (299), and
the standard incidence ratios for esophagus, stomach, and
small intestine cancers were 3.1, 2.5, and 6.2, respectively. As
previously discussed in Section IV.A, however, many of the
conclusions drawn by this study constitute a matter of con-
cern. Remarkably, other studies failed to demonstrate similar
data (10, 12, 342, 343). On the other hand, the past two
decades have provided overwhelming evidence that acro-
megaly especially stimulates the development of colon ad-
enomatous polyps. Colon adenomas are regarded as benign
glandular dysplastic lesions carrying a high cellular prolif-
eration rate, enlarged and hyperchromatic nuclei, and re-
duced cytoplasmic mucin (344). The cellular architecture
identifies tubular, villous, or tubulovillous adenomas, with
tubular and tubulovillous being the predominant types
found in acromegaly. The existence of similarities between
colon adenomas and carcinomas indicates a temporal link
between these lesions; minute carcinomas are adenomatous
in origin; adenomas and carcinomas share homologies in
morphology, clonality, genetic mutations, and chromosomal
deletions; familial adenomatous polyposis predisposes to
colon cancer; adenomas and carcinomas often arise from the
same area; and adenomas may swap into cancer within
10–15 yr of their onset (344). Mutation in tumor suppressor
genes, such as adenomatous polyposis coli and p53, DDC
(deleted in colon cancer), and DNA mismatch repair genes
have been additionally isolated in colon adenomas and car-
cinomas (345). Very recently, a reduced expression of per-
oxisome proliferator-activated receptor- was found in the
colonic mucosa of patients with active acromegaly (346); the
expression of peroxisome proliferator-activated receptor-
was inversely correlated with IGF-I levels, suggesting a di-
rect role of this factor in the increased prevalence of colonic
polyps. As in the general population, colon adenomas iden-
tify individuals at increased risk for colorectal cancer in pa-
tients with acromegaly. The first demonstration of an in-
creased occurrence of premalignant colon polyps in
acromegaly was provided almost two decades ago by Klein
et al. (295), documenting nearly a 30% prevalence of colon
adenomatous polyps in a prospective colonoscopy analysis
in 17 patients with acromegaly. By retrospective review of
this patient group as well as charts from 26 further patients,
a total of four colon cancers were accounted (295). Several
reports that followed have provided evidence that acrome-
galic patients are more prone to develop colon adenomas; on
average, 24% of patients screened for colon disorders harbor
colon adenomas (19). This estimate is representative of rates
fluctuating between 9 and 38% across different studies, a
wide range that may reflect dissimilarities in the selection of
patients and/or controls, as well as in the gender prevalence,
age, and adequate colon visualization. Terzolo et al. (347)
studied 113 patients with acromegaly and compared colono-
scopic results to those obtained in a control population un-
dergoing colonoscopy because of hematochezia. Patients
with acromegaly exhibited a greater prevalence of colon
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adenomas (38% vs. 14%; P 0.001), hyperplastic polyps (26%
vs. 10%; P  0.001), as well as multiple adenomas (57% vs.
29%). The difference between the two groups remained sig-
nificant at ages below 50 yr (46% vs. 7% of controls; P 
0.001). GH/IGF-I levels as well as activity or duration of
acromegaly appeared not to play any role in colonoscopic
findings. Similar results were obtained by Delhougne et al.
(348), recording a greater prevalence of adenomatous (22.3%
vs. 8%; P 0.01) and hyperplastic polyps (24.3% vs. 4.4%; P
0.001) in acromegaly than in their control group. Like Ter-
zolo’s study, the finding of a higher prevalence of polyps in
patients under the age of 55 yr (20% vs. 3% of controls)
appeared to suggest an anticipated occurrence of adenomas
in acromegaly, although both the duration and the activity
of acromegaly did not influence the prevalence observed
(348). In the Jenkins’ series (349), tubulovillous adenomas
were detected in 34 patients (29%), 53% of whom had mul-
tiple adenomas. Expectedly, aging predicted the occurrence
of colon adenomas, because the proportion of patients with
one or more adenomas increased with each decade, so that
39% of patients aged over 70 yr harbored at least one ade-
noma. Compared with a screening study on left-sided ade-
nomas in asymptomatic subjects, the prevalence of left-sided
adenomas reported by Jenkins et al. (349) was significantly
higher in acromegalic patients at ages above 49 yr, providing
an odds ratio of 4.2. A study performed by our group (338)
located two thirds of adenomas in the proximal colon; the
prevalence (22% vs. 5.7%; P  0.01), synchronicity, and dys-
plasia of adenomas was significantly greater in acromegaly
than in the control group, although the number of polyps was
unrelated to disease duration and GH/IGF-I levels. The se-
lection of our control group included subjects referred to
colonoscopy because of irritable bowel syndrome. As in the
studies of others in which control subjects were subjected to
colonoscopy because of various bowel disturbances, the ab-
sence of a perfectly matched healthy population in our study
may constitute a significant caveat in the interpretation of
results. At variance with previous studies, the prevalence of
colon adenomas reported by Renehan et al. (335) in their
series of 115 patients recruited from two different centers was
strikingly lower than in previous reports. The observed prev-
alence summed up to 9.5% and increased proportionately
with patients’ age; no adenoma was diagnosed under 40 yr
(17 patients), whereas progressively increasing rates of 8, 12,
20, and 21% were recorded for decades of 40–49, 50–59,
60–69 and more than 70 yr. Five of 11 patients with adeno-
mas (45% of this subgroup) had multiple polyps, whereas 18
subjects (16% of the whole series) had hyperplastic polyps.
Interestingly, the significance of these findings was tested
against a binary control model: eight autopsy studies en-
compassing 3559 exams of bowels from noncancerous pa-
tients, and four colonoscopy screening studies performed on
810 asymptomatic subjects with no family history of colo-
rectal cancer (335). Such a comparison failed to demonstrate
differences in adenoma prevalence between these control
models and acromegaly, where adenomas exhibited a less
advanced degree of dysplasia than in the control models. Of
note, acromegalic patients with neoplasia were, on average,
10 yr older and had received colonoscopy 4 yr later than
patients without neoplasia. Nevertheless, it has been noted
that the observed 20% prevalence of adenomas reported by
Renehan et al. (335) in patients older than 50 yr is similar to
the rates reported in previous studies and outnumbers the
generally accepted control prevalence of 9% (24). On the
basis of the above-mentioned studies, indication emerges
that acromegaly increases the risk of developing colon ad-
enomas after the age of 50 yr and that colon adenomas
developing in acromegaly share several clinical-pathological
features: 1) although adenomatous polyps may virtually
arise from any colon site, the involvement of ascending colon
in acromegaly is variably predominant and is estimated to
account for 5% (343), 21% (338, 349), 25% (347), 35% (348),
45% (350), and 68% (335) of cases; 2) polyp size is usually
larger in acromegaly than in controls from a normal popu-
lation: 3–15 mm vs. 4–10 mm (mean, 9 mm vs. 6 mm) in the
study by Vasen et al. (350) and 7–28 mm vs. 5–14 mm (mean,
18.4 mm vs. 9 mm) in the study published by our group (338);
in line with these observations, Jenkins et al. (349) reported
evidence of polyps ranging from 5 to 35 mm in their series,
whereas Renehan et al. (335) indicated a significantly higher
prevalence (P 0.01) of adenomas sized greater than 10 mm
in acromegaly compared with control models; 3) colon ad-
enomas in acromegaly occur more frequently after the age of
50 yr, and they predominate in males, in patients with dis-
ease duration longer than 5 yr, in those with three or more
skin tags, as well as in the case of a family history of colon
polyps; 4) conversely, disease activity, GH and IGF-I levels,
years of exposure to high GH and IGF-I levels as well as
familiarity for colon cancer do not predict the occurrence of
colon adenomas (Table 5) (295–297, 335, 342, 343, 347–354).
The issue of whether the enhanced frequency of prema-
lignant colon lesions implies a higher prevalence of colon
cancers is, however, still a matter of debate, due to divergent
conclusions reached in diverse epidemiology studies. The
findings of a high cancer mortality in acromegaly reported
in the retrospective studies published by Wright et al. in 1970
(12) and Alexander et al. in 1980 (8) were instrumental in the
publication of four retrospective/prospective studies be-
tween 1982 and 1990, reporting 11 cases of colon cancer
among 156 acromegalic patients (295–297, 352). This associ-
ation was later supported by the findings of Ron et al. (299)
of a 3-fold higher incidence of colon cancers in acromegalic
men compared with in-hospital nonacromegalic patients.
Despite its caveats, this latter study convinced many re-
searchers of an enhanced colon cancer risk in acromegaly,
thus endorsing further prospective research. Prospective se-
ries of colonoscopy screening studies in patients with acro-
megaly have revealed 25 cases of cancer out of 681 exami-
nations (24), and colorectal cancers have been calculated to
affect 2.5% to 3.7% of acromegalic patients (19, 24). In their
series, Jenkins et al. (349) found six cases of colon adenocar-
cinomas in 129 patients, yielding a 5% prevalence in the
group as a whole. Carcinomas were diagnosed at an average
age of 66 yr and did not show any colon site preference, with
two cancers located at the caecum, one at the splenic flexure,
and the remaining three at the rectosigmoid area. None of the
patients fulfilled criteria for either hereditary nonpolyposis
colonic rectal cancer or familial adenomatous polyposis. By
comparing multiple control models, the authors recorded a
13.5-fold greater prevalence of colon cancer compared with
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a published series of 621 asymptomatic subjects and a rate
92.6-fold higher than age-matched Southeast England inci-
dence rates (349). Such findings have been subsequently
extended by the observation of four additional malignancies
in a total of 155 patients, giving a combined prevalence of
6.5%. The results achieved in our concomitant prospective
study (338) were somewhat in line with Jenkins’ findings.
Our observed prevalence rate of colon cancer in acromegaly
was not significantly greater (2% vs. 1.2%) than that in our
control population of subjects with irritable bowel syndrome
(338), although another patient was diagnosed with a caecum
adenocarcinoma soon after the publication of our study.
More intriguing observations originated, however, from
Renehan’s study (335), which found three cases of colon
cancer in 115 acromegalic patients, giving an overall prev-
alence of 2.6%. This rate proved to be similar to that recorded
in autopsy (2.3%) and in vivo screening (0.9%) control mod-
els. Although adenomas tended to be right-sided, all neo-
plasms were detected in the recto-sigmoid area. Of note, two
of three patients with carcinoma were 79 and 81 yr old, an
age significantly older than the average age of 66 yr recorded
in neoplastic patients by Jenkins et al. (349). On the basis of
their findings, Renehan et al. (351) have indicated that acro-
megaly does not enhance the risk of colon malignancy and
have thus questioned the policy of an aggressive diagnostic
approach for colon disorders in acromegaly (Fig. 12). How-
ever, the control models used in this study by Renehan et al.
have drawn a number of criticisms. Autopsy bowel exami-
nations involve optimized visualization conditions, i.e., de-
tailed and magnified visualization of uncontaminated tis-
sues, a circumstance that allows detection and excision of
even minute lesions. Conversely, colonoscopy is associated
with a significant miss rate for polyps sized less than 1 cm
(355), and vigorous bowel preparation is additionally re-
quired in patients with acromegaly to compensate for the
increased colon length (335). It is also significant that the
control colonoscopy studies used in Renehan’s study
showed a nearly 3-fold greater prevalence of males, which
may have overestimated the general cancer prevalence be-
cause colon adenomas/cancers are more frequent in males.
A series of colonoscopy screening programs including nearly
6,000 asymptomatic subjects have reported colon cancer
prevalence rates between 0.3 and 0.4% (356, 357) and 0.9%
(358), but this latter study was biased by a tendency to select
male subjects exposed to colon disorders and with a family
history of colon cancer. Taking these circumstances into ac-
count, Renehan’s results may be partly viewed in support of
a positive association between acromegaly and colon cancer
risk. In a recent retrospective study, Baris et al. (359) have
collected 1634 cases of acromegaly in Sweden and Denmark
and documented a value of SIR of digestive cancers 2.1-fold
greater than in the control population. The incidence rate of
colon and rectal cancers was 2.6- and 2.5-fold higher than
normal, respectively, but risks were also enhanced for can-
cers of the brain, thyroid, kidney, and bones (standardized
incidence rates equal to 2.7, 3.7, 3.2, and 13.8%, respectively).
Another relevant issue is constituted by the influence of age
and disease activity on colon cancer risk. Most prospective
studies have indicated that colon carcinomas arise especially
after the age of 50 yr, but up to one third of reported cancers
have been diagnosed before age 55 yr (247, 296–298, 300, 301,
335, 352, 354). As noted by Atkin (360), colon cancer risk is
highest just before the diagnosis of acromegaly, suggesting
that the risk may increase in untreated disease. The Orme et
al. study (18) showed that acromegaly quasi-significantly
increased the incidence rates of colon cancer (P  0.06 at
one-sided Poisson probability). The finding of a 2.5-fold
greater colon cancer mortality was speculatively attributed
to the finding of higher posttreatment values of GH in pa-
tients with cancer (18). Consistent with this interpretation,
colon cancer mortality was increased by three times in case
of posttreatment GH levels between 2.5 and 9.9 g/liter and
by nearly five times for GH levels above 10g/liter. Renehan
et al. (335) reported a nonsignificant increase in the preva-
lence of colonic lesions between active and inactive patients
(18% vs. 6%), but they did not find any association between
IGF-I or IGFBP-3 and the presence of adenomatous polyps.
These findings would be in agreement with the observation
that persistent elevation of GH/IGF-I levels increases the
residual risk of developing colon tumors in the short term,
as indicated in a follow-up study performed by Jenkins et al.
(361). The authors recorded a recurrence of colon polyps in
14% of patients examined within 3–36 months after initial
colonoscopy, and IGF-I was used as a surrogate to predict
tumor recurrence rate: in fact, the relative risk of a new
adenoma increased to 10.3 in case of elevated IGF-I levels
(Fig. 13) (361). Colonoscopy studies have also provided in-
formation that carcinomas developing in acromegaly can
potentially arise from any colon site and that patients can be
asymptomatic for years; therefore, the finding of different
degrees of colon wall infiltration, reportedly ranging from
Dukes stage A through D at diagnosis, is not surprising (296,
335, 347, 354), although disseminated cancers are definitely
rare (296, 352). Significantly, no information exists at the
moment on clinical evolution and chemotherapeutic respon-
siveness of colon cancers in acromegaly.
Another unresolved issue is the screening age and, hence,
the screening intervals in which patients should undergo
colonoscopy. In the asymptomatic general population,
colonoscopy at age 55, followed by adenoma excision, re-
duces the colon cancer risk (362, 363). The recurrence rate of
FIG. 12. Cumulative incidence of colorectal cancer by age in groups
with hereditary predisposition and acromegaly compared with the
general population. [Adapted from A. G. Renehan et al.: Clin Endo-
crinol (Oxf) 55:731–733, 2001 (351). Permission granted by Blackwell
Science.]
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adenomas is 37%, and the occurrence of newly diagnosed
adenomas is 19% within 1–5 yr after the first exam (364).
Patients with large and/or multiple adenomas at baseline
screening colonoscopy are at a 2.6- to 4.5-fold risk for recur-
rence of adenomas (364). Compared with controls, the risk of
developing adenomatous polyps in acromegaly is usually
enhanced, anticipated, more frequently synchronous, and of
larger size. Consistent with this evidence, Jenkins et al. (349)
found it prudent to perform full-length colonoscopy at age
40 yr and, later, every 3 yr in case of adenoma/cancer or
elevated IGF-I levels; if the first colonoscopy is negative, a
5-yr interval should be sufficient. However, Renehan et al.
(351) indicated that patients with acromegaly are only ex-
posed to a moderate risk of developing colon tumors and
should be examined therefore according to the screening
criteria approved for patients with hereditary polyposis syn-
dromes (at very high risk), those with family history of colon
cancer (at high risk), and the normal population (Fig. 12).
These authors additionally calculated that 556 colonoscopy
exams would be needed over a 10-yr period to prevent one
colorectal cancer death. On these bases, they suggested that
the first colonoscopy should be performed around age 50 yr
(351). In her “independent view” report, Atkin (360) consid-
ered that a 2.5- to 3-fold increased risk of colorectal cancer
strongly suggests that patients might benefit from a single
sigmoidoscopy or colonoscopy at around age 55 yr. In our
practice, we advise patients to undergo full-length colonos-
copy at age 50 yr, independent of activity/duration of ac-
romegaly as well as family history of colon disease, unless
symptoms of bowel disorders occur earlier. Prerequisites for
adequate colonoscopy are an accurate bowel preparation
with efficacious enema, as well as examination being per-
formed by an experienced operator, to overcome the en-
hanced difficulty that this type of exam implies in acromeg-
aly. In case of colon cancer, patients should undergo exams
yearly for the first 3 yr after surgical removal and then every
third year. We also suggest performing colonoscopy every 3
yr when patients have been found with adenomas at first
visit, especially if synchronous or larger than 10 mm, or if
patients are scarcely responsive or resistant to acromegaly
treatments. Conversely, we choose a 5-yr colonoscopy pro-
gram if patients are negative for colon polyps.
D. Neck and lung tumors
1. Thyroid tumors. GH and IGF-I excess causes thyroid over-
growth, which is usually considered one typical aspect of the
visceromegaly developing in acromegaly. Experimental
work has demonstrated not only that IGF-I increases prolif-
eration of porcine thyroid cells and FRTL-5 rat thyroid cells,
but also that it potentiates TSH-mediated thyroid cell pro-
liferation (365). Indirect evidence of a positive role for GH
and IGF-I in thyroid growth is based on the antiproliferative
effect exerted by hypophysectomy on TSH-mediated thyroid
growth in rats (366) and, oppositely, by the stimulatory ac-
tion elicited by incubation of FRTL-5 cells with serum from
acromegalic patients (367). The existence of a local IGF-I-
mediated autocrine loop is suggested by the detection of
IGF-I production in follicular thyroid cells (368), papillary
cell lines (369), and surgical thyroid specimens in which IGF-I
synthesis is greater in tumoral than in normal tissue (370).
Affinity cross-linking studies have shown the presence of
IGF-I receptor in follicular and papillary cancer cells, as well
as in tumoral tissue specimens.
Although benign thyroid overgrowth is a common phe-
nomenon in acromegaly, the occurrence of thyroid tumors
constitutes a relatively rare event in this condition (Table 5).
Neck palpation and ultrasonography reveal goiter in 25–92%
of cases, independent of TSH levels, whereas a positive re-
lationship between GH/IGF-I levels and thyroid volume has
been debatably documented (371–375). Multinodular goiter
is detected in 65% of patients, and the chance of developing
thyroid nodules increases with increasing disease duration
(371, 374). Nodular goiter is toxic in 14% of patients (375), but
the prevalence of hyperthyroidism reportedly ranges be-
tween 3.5 and 26% in unselected patients from different
investigations (9, 136, 372, 375). In a study performed by our
group, seven of eight patients who developed thyrotoxicosis
were undergoing octreotide treatment at the time of onset of
the disease (136). Unlike the general population, the influ-
ence of gender on the prevalence in thyroid disorders is
seemingly null in acromegaly (375). Thyroid nodules are
usually benign. At histology, colloidal, hyperplastic, or ad-
enomatous aspects of thyroid tissue have been described (9,
295). In the study by Gasperi et al. (375) thyroid biopsy was
performed in seven cases and showed histological patterns
of microfollicular architecture (n  2), Hurthle cells (n  2),
cellular dysplasia (n  2), and papillary thyroid carcinoma
in one patient, whereas two others were found to harbor
papillary thyroid cancers. Overall, thyroid cancers constitute
3.1% of malignant events in acromegaly (9, 10, 297, 298, 376);
the incidence of this cancer significantly increased by 3.3%-
fold only in the study by Baris et al. (359). Thyroid tumors are
predominantly papillary and occasionally aggressive, as con-
firmed by the rare occurrence of multifocal tumors (377) and
by low mortality rates (9, 297, 298). The studies reviewed and
our experience indicate that acromegaly enhances the risk of
developing goiter, although the prevalence of thyroid can-
FIG. 13. The mean (SEM) serum IGF-I at the second colonoscopy in
66 patients with acromegaly with colorectal adenomas, hyperplastic
polyps, or normal colon. [From P. J. Jenkins et al.: J Clin Endocrinol
Metab 85:3218–3221, 2000 (361). Permission granted by The Endo-
crine Society.]
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cers is not different from normal. Thyroid enlargement seems
to occur independently of endemic, nutritional, and hered-
itary factors, but it is reportedly associated with aging, years
of exposure to GH/IGF-I hypersecretion, as well as IGF-I
levels. In the setting of a multinodular goiter, prudence
should be used when starting thyroid suppressive therapy
with l-T4 due to an apparently enhanced risk of thyrotoxi-
cosis. Because the rate of benign and malignant thyroid tu-
mors appears to be similar to that recorded in the general
population, acromegalic patients should undergo standard
periodical examinations of thyroid morphology and
function.
2. Lung tumors. The relationship between lung cancers and
the IGF system has been suggested by experimental studies,
demonstrating that IGF-IR expression occurs in small cell
lung cancer (SCLC) and non-SCLC, as well as in normal and
tumoral lung tissue (313). Autocrine IGF-I synthesis has been
detected in lung cancer specimens and SCLC lines (378).
IGI-I/IGF-IR stimulation and IGF-IR overexpression cause
lung cancer cell proliferation and increase the metastatic
activity of lung cancer cells; conversely, tumor growth pro-
gression is abolished by blockade of IGF-IR by IR3 antibody
(379, 380). An ongoing hospital-based case-control study de-
tected a dose-dependent association between circulating
IGF-I levels and lung cancer risk (odds ratio, 2.06) and a
negative association with IGFBP-3 levels (381). The relation-
ship between acromegaly and lung tumors emerged in the
study of Mustacchi and Shimkin (294), where three cases of
lung cancer were mentioned. In the study published by
Wright et al. in 1970 (12), lung cancer mortality accounted for
three of 10 cancer deaths. Similar records were obtained by
Nabarro (9) and Bengtsson et al. (10), each reporting two
deaths from this malignancy. In the general population, lung
cancer affects the male gender more frequently, and the
finding of 22 bronchial and seven oropharyngeal tumors in
the Ron et al. study (299) on acromegalic men is, therefore, not
surprising. These authors failed to record any significant
difference in the lung cancer prevalence compared with
nonacromegalic hospital controls. Similar observations were
reported in the study by Orme et al. (18) in which both the
incidence and the mortality from lung cancer were even
lower than the expected rates.
E. Tumors of the reproductive system
1. Breast and female reproductive system. There is a tight link
between the growth regulatory pathways of IGFs, and es-
trogen-receptor positive breast cancer cells in an in vivo study
suggest a role of IGF-I and IGF-IR in breast cancer develop-
ment (383). The relevance of GH/IGF-I involvement in breast
tumors emerged in studies where extracted GH given chron-
ically to female rats induced breast tumors over the long term
(303). Mammary tissue expresses both GH-R and PRL-R, but
only human GH is able to activate either receptor in primates
and nonprimates, whereas nonprimate GH acts only through
the GH-R and PRL acts only through the PRL-R (382). In
mutant lit/lit mice carrying a mutation of the GHRH recep-
tor, which thus blunts GH secretion, the growth of mammary
tumor transplants is dramatically reduced (305), whereas
mice transgenic for human GH were shown to develop preg-
nancy-independent metastatic mammary tumors through
activation of the PRL-R (307). Experiments in other mammals
appear to suggest that this tumor-promoting effect may be
species-related. In fact, a 7-wk treatment with GH and/or
IGF-I in rhesus monkeys caused the nontumoral prolifera-
tion of both stromal and epithelial mammary cells (384).
Interestingly, GH-treated animals showed a greater rate of
mammary lobule number and size than IGF-I-treated coun-
terparts, suggesting a direct GH effect additional to that
mediated by IGF-I. In humans, the GH-R is expressed in
mammary tumors and cell lines, and although the expression
of GH-R and PRL-R is primarily localized in epithelial cells,
some expression is also evident in stromal cells (385). The
additional finding of GH and PRL protein expression in
mammary tumors as well as normal tissue appears to suggest
a possible autocrine/paracrine role of these hormones on
tumor development and growth (382). In line with this hy-
pothesis, studies in MCF-7 mammary cancer cell lines have
shown that blockade of GH-R by the specific GH-antagonist
B2036 was capable of abrogating tyrosine phosphorylation of
JAK2, cellular proliferation, and apoptosis mediated by au-
tocrine GH (309). Similarly, the relevance of the IGF system
in breast cancer has been suggested by studies demonstrat-
ing the existence of a polarized IGF-I/IGF-IR loop, where
stromal cells can stimulate epithelial cells to grow via para-
crine mechanisms. IGF-I is secreted in the conditioned me-
dium of human breast cancer cell lines (386), whereas Rnase
protection assays and in situ hybridization studies have iden-
tified the stromal tissue of breast cancer specimens as the
source of IGF-I (387, 388). As in other cancer cell lines, ex-
ogenous addition of IGF-I to breast cancer cells promotes cell
proliferation, and this effect can be prevented by stimulation
with anti-IGF-IR antibody IR3 (389). Conversely, IGF-IR
mRNA is expressed on the surface of primary cultures of
malignant breast epithelial cells (390) as well as in several
estrogen-dependent and, at lower amounts, in estrogen-
independent cell lines, where the expression of IGF-IR is
positively correlated with that of estrogen (ER), progesterone
(PR), and PRL receptors (391). The correlation between
IGF-IR expression and the ER status in breast cancer speci-
mens has been further confirmed in studies in which IGF-IR
expression was significantly higher in specimens from
ER/PR positive tumors at lower degree of risk than in ER/PR
negative tumor at higher risk, thus suggesting a predictive
role for IGF-IR as a good prognostic factor (392). From a
clinical perspective, sex steroids can modulate the GH/IGF-I
axis at many levels, including pituitary GH secretion, secre-
tion of liver IGF-I as well as production of IGFBPs, which is
ultimately reflected in IGF-I clearance rate (312). No consen-
sus estrogen-responsive element has been identified in IGF-I
promoters, but studies in chicken IGF-I gene P1 promoter
have identified the AP-1 enhancer as a mediator of estrogen
responsiveness, whereas time- and dose-dependent induc-
tion of IGF-I gene expression by estradiol treatment has been
observed in human fetal osteoblasts (316). Because the con-
centrations of ovarian steroids are higher in the premeno-
pausal stage, a greater effect of estrogen steroids on IGF-I
levels may explain the results of studies exploring the rela-
tionship between IGF-I levels and breast cancer risk in pre-
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menopausal women. As discussed above, breast cancer risk
developing in premenopausal women has been suggested to
be directly related to serum IGF-I and inversely related to
serum IGFBP-3. Hankinson et al. (51) found that stratification
of breast cancer-bearing patients by progressively increasing
tertiles of IGF-I levels allowed them to identify a 2.6-fold
greater risk of breast cancer in the group with the highest
IGF-I levels; in premenopausal women less than 50 yr old,
high IGF-I tertiles alone predicted a 4.6-fold higher risk and,
in combination with low IGFBP-3, a 7.3-fold higher risk than
in unaffected women. On the other hand, analysis of reports
on breast cancers in acromegaly reveals an average preva-
lence of 1.7% for this type of tumor. As a whole, breast
cancers represent 13% of all malignancies developing in ac-
romegaly and cause nearly 11% of cancer-related deaths in
acromegaly (Table 5). Despite these figures, reports focusing
on mammary tumors are predominantly epidemiological
and fail to provide an accurate insight into the problem.
Nabarro’s findings (9) attracted attention on a 4-fold higher
incidence of breast cancer in acromegalic women, although
the strong association between acromegaly and breast cancer
was in apparent conflict with the low mortality from breast
cancer observed in this study. Conversely, Orme et al. (18) did
not find any increase in either the incidence or mortality from
mammary tumors compared with the general rates, although
the mortality from breast cancer was 60% higher than in
normal women and increased by 3-fold in the case of post-
treatment GH values above 10 g/liter. Several studies have
noted that a short interval (on average, 5 yr) generally sep-
arates the diagnosis of acromegaly from that of breast cancer,
thus suggesting that risk may increase in the short term
and/or in the presence of untreated disease (298, 301).
On the other hand, only a few reports have been published
on the occurrence of cancers at the level of the female re-
productive system, thus suggesting indirectly that uterine
and ovarian tumors are much less common. Remarkably, a
significant increase in the occurrence of uterine leiomyomata
has been documented in nearly 80% of women in a small
study (393). Oppositely, ovarian and uterine carcinomas are
rare (Table 5); indirect evidence exists that uterine cancers
may develop earlier in life and with shorter disease duration
than ovarian carcinomas (9, 295, 298, 301, 352).
2. Prostate and the male reproductive system. As in breast tu-
mors, the link between IGF-I and prostate tumorigenesis has
experimental and clinical bases. Both normal and tumoral
prostate cells express negligible amounts of IGF-I mRNA,
which is increased in prostate tumors from transgenic ade-
nocarcinoma of mouse prostate models, in which the severity
of cancer progression seems to be directly correlated with
IGF-I expression (394, 395). PC-3, DU-45, and LNCaP cancer
cell lines do not produce IGF-I, whereas the elevated expres-
sion of IGF-IR mRNA constitutes a prerequisite for IGF-I to
stimulate proliferation in these prostate cancer cell lines,
which is, as a consequence, abrogated by transfection with
antisense oligonucleotides complementary to IGF-IR mRNA
(for review, see Refs. 313, 396, and 397). Conversely, the loss
in IGF-IR mRNA expression documented in tumors from
castrated transgenic adenocarcinoma of mouse prostate mice
has been interpreted as a mechanism leading to dedifferen-
tiation and greater tumorigenicity. Androgen sensitivity may
similarly drive the proliferative response under IGF-I stim-
ulation. In androgen-independent prostate cancer cells, such
as PC-3 and DU-45, IGF-I causes cell proliferation regardless
of the presence of androgens in culture media, whereas cul-
tures of androgen-dependent cells, such as LNCaP, become
responsive to IGF-I only in the presence of dihydrotestos-
terone (396). Transfection of rat PA-III prostate adenocarci-
noma cells with an IGF-IR antisense construct reduced IGF-I
mRNA levels in these cells, whereas injection with trans-
fected PA-III cells induced tumors that were approximately
90% smaller than controls (398). One relevant phenomenon,
which may explain some of the prostate alterations seen in
acromegaly, is constituted by the observation that stromal
cells derived from benign prostatic hyperplasia express
IGF-IR mRNA and that IGF-I stimulation increases stromal
cell density by 80%, an effect that is abrogated by coincu-
bation with the IGF-IR-neutralizing antibody  IR3 (399). In
humans, serum IGF-I levels appear to predict both risk and
growth rate of prostate cancers, and the aforementioned
study by Chan et al. (50) attributed to IGF-I the role of pre-
dictor of prostate cancer. In a subsequent nested case-control
study on 530 patients with prostate cancer, IGF-I and IG-
FBP-3 levels appeared to predict the progression of
advanced-stage prostate cancers, the relative risks being 5.1
for the highest vs. the lowest IGF-I quartiles and 0.2 for the
highest vs. the lowest IGFBP-3 quartiles; combination of high
IGF-I and low IGFBP-3 increased the relative risk to 9.5,
whereas the combination of IGF-I and IGFBP-3 with values
of prostate-specific antigen (PSA) increased the specificity
from 91 to 93% but decreased sensitivity from 40 to 36% (400).
The role of PSA remains, however, significantly more pre-
dictive than IGF-I in men with prostate cancers and elevated
levels of PSA; the analysis of ratios of IGF-I, IGFBP-3, and free
and total PSA does not seem to further improve the accuracy
of PSA measurements alone (401, 402).
Acromegaly predisposes to benign prostate hypertrophy,
the condition of stromal proliferation of the prostate. A pilot
transrectal ultrasonography study revealed a marked in-
crease of prostate volume and of the transitional zone in
untreated acromegalic males, regardless of gonadal status
and age of patients (403). In fact, all patients screened by
transrectal ultrasonography study were found to be hypogo-
nadal and were aged below 40 yr. In a larger series, including
patients with active or cured acromegaly and postsurgical
hypopituitarism, benign prostate enlargement (that is, vol-
ume exceeding 30 ml by ellipsoidal formula) occurred in 80%
of active patients, 30% of cured acromegalic patients, none of
the GH-deficient patients, and 26% of controls (404). At mul-
tiple regression analysis, prostate volume correlated signif-
icantly more with disease duration than with patients’ age.
Additional findings were represented by the development of
calcifications in 61%, cysts in 26%, vesicle inflammation in
8%, and biopsy-proven benign nodules in 13% of acrome-
galic patients (404). On the other hand, and at variance with
the indication that IGF-I links to prostate cancer risk in the
normal population, acromegalic patients harbor a decreased
risk of prostate cancers. This inference emerges mostly from
epidemiology studies in which the number of prostate can-
cers constitutes a minority of malignancies and are signifi-
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cantly less prevalent that in the normal population (Table 5).
In 1970, Campbell and Harrison suggested that acromegaly
did not predispose to prostate enlargement (405), and Kra-
witt’s description, 3 yr later, of a 75-yr-old acromegalic man
deceased after unsuccessful removal of a giant invasive pros-
tate cancer remains anecdotal (406). In the largest study pub-
lished on acromegalic men, 15 tumors arising from the gen-
itourinary tract accounted for a 17% prevalence among all
nonpituitary cancers, a rate nonsignificantly different from
that recorded in the nonacromegalic control population en-
rolled in VA hospitals (299). Although unique among all
epidemiology studies, however, the relevance of this obser-
vation is blunted by a pooled presentation of genitourinary
tumors. Intriguingly, the absence of prostate cancers in any
of the patients screened in our studies constitutes a relevant
caveat in the theory linking IGF-I levels to prostate cancer in
the general population. In this regard, Cohen et al. (407) have
indicated a series of hypotheses to explain the observed
relationship between IGF-I and prostate/breast cancer risk
that are worth considering: 1) the observation may have
originated from an ascertainment bias or a methodological
error; 2) other cancer-controlling factors, such as nutrition,
may have modulated IGF-I concentrations, which then act as
a confounding factor rather than as cause of cancer; 3) tumors
may work as a source of IGF-I, which can thus be considered
as a tumor marker; 4) it is possible that autocrine IGF-I
production is involved in the pathogenesis of a number of
tumors, including those linked to increased circulating IGF-I
levels; and 5) it is possible that IGF-I elevation reflects GH
action on some types of cancer. It is interesting to note,
however, that acromegaly also increases liver synthesis of
IGFBP-3, which has shown IGF-independent proapoptotic
and antitumoral effects at the local level, as discussed above.
Although IGFBP-3 levels appear to predict a less aggressive
behavior of breast, prostate, and colon cancers (50–52), it has
been shown that a number of tumors are associated with
increased IGFBP-3 proteolysis in the serum (49), which nor-
mally acts to release IGF-I locally. Because PSA also functions
as a major IGFBP-3 protease, thus serum PSA elevation in
prostate cancer-bearing patients may indirectly promote free
IGF-I release locally. This possible mechanism is not appli-
cable in acromegaly where IGFBP-3 proteolysis is not in-
creased; speculatively, this circumstance may even protect
acromegalic patients against the development of prostate
cancers. However, this issue awaits further clarification. Of
note, the return of GH and IGF-I levels to normal has ben-
eficial effects on the prostate in acromegaly. Two years of
treatment with lanreotide, together with a GH, IGF-I, and
IGFBP-3 level decrease, induced a decrease of prostate vol-
ume in 16 patients well controlled by the treatment (408).
Prostate volume decreased after treatment only in the eight
controlled patients younger than 50 yr, but not in those
controlled with age above 50 yr, despite a similar decrease in
GH, IGF-I, and IGFBP3 levels. Taken together, these data
appear to indicate that chronic elevation of GH and IGF-I
levels constitutes a proliferative stimulus for stromal cells of
the prostate independent of the androgen status. Thus, pros-
tate epithelial cells appear not to be targeted by GH/IGF-I
excess, although more extensive follow-ups are necessary to
fully understand this observation.
F. Other tumors
At the level of the genitourinary tract, GH excess affects
renal function and kidney size and increases glomerular
filtration rate and renal plasma flow in GH-deficient as well
as normal adults. IGF-I is implicated in compensatory renal
hypertrophy, whereas markedly elevated serum GH levels
accelerate glomerular sclerosis in rodents. Measurement of
absolute glomerular size using a semiautomatic image ana-
lyzer revealed heavier kidneys in acromegalic patients than
in controls (409). Histological comparison between acrome-
galic patients and subjects with single kidneys showed more
global glomerulosclerosis and segmental lesions in single
kidneys, a finding that likely implies different mechanisms
for the renal enlargement seen in acromegaly. Functionally,
submaximal exercise induces abnormal increases in mi-
croalbuminuria in patients with acromegaly, although 1-
microglobulinuria levels, a marker of renal tubular damage,
were normal both at rest and at peak exercise (410). Unlike
these disorders, kidney cancers play an irrelevant role in
tumoral phenomena of acromegaly (Table 5). Similarly, scat-
tered reports have been published on brain tumors (299),
meningiomas (410), osseous tumors (294, 411), ocular mela-
nocytic nevi and melanoma (412), skin epidermoid cancers or
melanomas (294, 299), as well as adrenal tumors (10). De-
scription of lymphohematopoietic neoplasms includes lym-
phoma, multiple myeloma, chronic myelogenic or lympho-
cytic leukemia, and polycythemia vera (9, 294, 298, 299, 301,
352, 413). Among 106 patients treated for over 15 yr, Au et
al. (414) found two cases of acute lymphoblastic leukemia
and one patient with acute myeloid leukemia. Two of these
patients had received radiotherapy as part of their treatment.
At variance with other reports, the incidence of leukemia
adjusted for age and follow-up years was significantly higher
in this cohort than in the general population (414). The oc-
currence of lymphopoietic tumors in the late course of ac-
romegaly suggests, however, that these two conditions are
likely unrelated.
VI. The Complications at the Skeletal System
A. Epidemiology
As already stated, the osteoarticular manifestations fea-
ture the disease; symptoms or signs referable to articular joint
disorders occur in the great majority of patients with acro-
megaly at their diagnosis (415–417). The delay between the
estimated onset of acromegaly and the appearance of joint
disease is approximately 10 yr, but the range is wide and
oscillates between 0 and 27.5 yr, according to the report by
Detenbeck et al. (418). Early signs of joint involvement were
also noted in patients with short disease duration (419). The
duration of acromegaly does not seem to be correlated with
the presence and/or the severity of arthropathy (415, 420,
421), although the patients with arthropathy included in the
study of Bluestone et al. (420) had severe and long-standing
acromegaly. Articular manifestations include articular in-
volvement and enthesopathy and are a leading cause of
morbidity and functional disability in these patients (418,
420, 422). Crepitus on clinical examination is the most com-
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mon sign (416, 418, 420, 423), whereas pain is the most com-
mon symptom, usually intermittent and exacerbated by ac-
tivity (420).
The acromegalic arthropathy affects both axial and pe-
ripheral sites. The appendicular skeleton is involved in up to
74% of patients with moderate-to-severe involvement in one
third of cases (9, 418, 420); neck or back pain is also common,
occurring in more than half the patients, but abnormalities
could be detected in 20–25% of cases (417, 421). The knee is
the most commonly involved peripheral joint, followed by
the shoulder, hip, ankle, elbow, and joints of the hand (417,
418, 420). Joint stiffness and swelling are also common; in
1952 Kellgren et al. (416) reported joint swelling in 52% and
effusions in 40%, whereas prevalence rates reported 20 yr
later by Bluestone et al. (420) accounted for 21% and 5% of
patients, respectively. Acromegalic arthropathy is generally
noninflammatory (418, 423), although features of osteoar-
thritis frequently develop in later stages of the disease (416,
418, 420, 422–424). Sinovial aspirates showed that effusions
are degenerative without evidence of inflammation or crystal
deposition (416, 418, 420). As noted by Lieberman et al. (425),
the occurrence of hypermobility (15–30% of cases) or limi-
tation of joint movement (16–27% of cases) likely depends on
disease duration. The unusual bone disease that is occasion-
ally associated with acromegaly, the McCune-Albright syn-
drome, has not been considered in this paper for its peculiar
bone aspects.
B. Pathogenesis
The pathogenesis of arthropathy is complex, involving
both GH/IGF-I excess and secondary degenerative changes.
Most in vitro studies have focused on the effect of GH and
IGF-I in chondrocytes derived from the epiphysial growth
plate, which is metabolically active and whose function and
degree of differentiation follow a topographical organization
(425). However, the chondrocytes in adult articular cartilage
are consistently less active than their epiphysial plate coun-
terparts. These cells are found alone or in pairs in isolated
lacunae within the cartilage matrix and rarely divide (426).
They maintain the extracellular matrix through degradation
and replacement of collagen proteoglycans, glycosamino-
glycans, and other macromolecules (426), but their ability to
repair damaged cartilage is very limited (427). Of historical
note, the lack of in vitro response of cartilage to GH was the
cause leading Salmon and Daughaday (26) to propose the
existence of a secondary mediator later named IGF-I. Sub-
sequent studies in suspension chondrocytes cultures dem-
onstrated that GH preferentially stimulated growth and dif-
ferentiation of prechondrocytes from the resting cell layers
and increased their sensitivity to IGF-I (428, 429). Like other
cells, chondrocytes are able to synthesize and release IGF-I
locally (430). GH is an important stimulus for chondrocytes
IGF-I mRNA and peptide expression. Other cytokines, such
as TGF-, basic fibroblast growth factor, and insulin, also
stimulate chondrocyte growth (425). IGF-I binds specifically
to chondrocytes with a greater binding affinity for prolifer-
ative than for resting zone cells (431). IGF-I stimulates DNA
synthesis, cell replication, proteoglycan and glycosamino-
glycan synthesis in chondrocytes or explants from a variety
of animals and under a variety of culture conditions (425).
IGF-I is a relevant regulator of collagen synthesis, because it
can reverse the abnormalities in collagen synthesis based on
experimental models of ascorbate deficiency (432). The role
of GH and IGF-I in bone metabolism parallels their effects on
the articular cartilage. Stimulation of DNA synthesis and cell
proliferation by GH depends on the degree of cell differen-
tiation (433), but GH also stimulates production of alkaline
phosphatase (433) and collagen (434). As in the cartilage, GH
effects on osteoblasts are likely to be mediated through para-
crine IGF-I production, although circulating IGF-I also in-
fluences osteoblast metabolism (435). Additional effects of
IGF-I include increased mRNA levels of 1(I)-procollagen
(435, 436), increased noncollagen protein mRNA and peptide
synthesis (435–437), inhibition of protein degradation (438),
and increased bone production in organ culture (437). How-
ever, in analogy with other body tissues, IGF-I action on the
bone comprises interactions among IGF-I, IGF-I receptors,
and IGFBPs. At least four distinct IGFBPs (IGFBP-1, -2, -3,
and -4) are produced by various bone cells in culture, and
distinct studies have intriguingly suggested that IGFBP-3
may enhance (439), whereas IGFBP-4 may inhibit, IGF-I ac-
tion (440). Additionally, many osteotrophic factors including
PTH, TGF-, platelet-derived growth factor, estrogens, and
cortisol, contribute in regulating GH and IGF-I production by
osteoblasts (425). Although this complex system still needs to
be fully elucidated, it seems conceivable that IGF-I may act
to integrate multiple trophic signals controlling bone
metabolism.
Based on experimental evidence, the pathophysiology of
the acromegalic arthropathy may be hypothesized. At the
initial stage, GH excess stimulates local production of IGF-I
in cartilage which, combined with increased levels of circu-
lating IGF-I, results in replication and hyperfunction of ar-
ticular chondrocytes and increased matrix synthesis. The
cartilage begins to thicken, leading to widening of the joint
space, alteration of the normal geometry of the joint, and
hypermobility of joints (Fig. 14). At radiology, widening of
the joint spaces and periarticular soft tissue hypertrophy can
be documented. GH also stimulates connective cell hyper-
function, resulting in growth of periarticular structures; si-
novial hypertrophy further exacerbates the abnormal me-
chanical loading of the joint. At this stage arthropathy may
be reversed by control of GH and IGF-I hypersecretion (see
Section VI.C). Along with disease progression, fissures de-
velop onto the cartilage surface and gradually enlarge,
whereas regenerative fibrocartilage proliferates dispropor-
tionately more than in osteoarthritis, presumably as a result
of GH stimulation (425, 432). The regenerative fibrocartilage
frequently becomes calcified, resulting in osteophyte forma-
tion. In more advanced cases, fissures may extend to the
subchondral bone, widen, and become undercut, producing
ulceration of the articular cartilage. The underlying bone
shows accelerated turnover, eburnation, and subchondral
cyst formation. Ultimately, the articular cartilage becomes
thinned with narrowing of the joint space, a process that
shares many features with osteoarthritis. At this stage, the
acromegalic arthropathy cannot be any further improved by
GH and IGF-I suppression (Fig. 14).
136 Endocrine Reviews, February 2004, 25(1):102–152 Colao et al. • Acromegaly Complications
 on June 3, 2005 edrv.endojournals.orgDownloaded from 
C. The acromegalic arthropathy
Arthropathy is the most frequent complaining symptom
referred by patients with acromegaly at diagnosis, being the
most frequent and severe cause of morbidity and inability in
these patients. Radiological evidence of joint space widening
occurs early, whereas long-standing disease is characterized
by the narrowing of joint spaces, osteophytosis, and other
features of osteoarthritis (425, 441). Radiographical changes
in the peripheral joints are typically widespread. However,
the presence of radiological abnormalities and clinical man-
ifestations of arthropathy are not correlated, unless joints are
severely affected, as in long-standing disease (425). In fact,
joints of the hand are infrequently symptomatic but radio-
graphic changes are found in more than 50% of patients (322).
As already stated, changes include widened joint spaces,
distal tufting of the phalanges (Fig. 15), osteophyte formation
(especially of the base of the distal phalanges), enthesopathy
(mineralization of ligamentous insertions) (Fig. 16), and cal-
cification of the joint capsule (416–418, 420, 421). Eburnation
and subchondral cyst formation, reflecting severe cartilage
destruction, are less common. Abnormalities of radiograms
at knees and hip are also found in more than 50% of patients;
the knees show widening of the femorotibial and patellar
joint spaces, osteophytosis, enthesopathy, capsular calcifica-
tion, and occasionally chondrocalcinosis (415, 417, 418). In
more severe cases, evidence of effusion, narrowing of joint
space or angular deformity may occur (425). Joint space
widening, osteophyte formation and enthesopathy are es-
pecially common in the hip and shoulder. Severe degener-
ative changes of the hip are less frequent and are frequently
unilateral; this may occur in elderly patients with very long
duration of exposure to high GH and IGF-I levels. In our
series, five patients out of 45 aged above 60 yr (11%) had
undergone surgical joint replacement at one femur head (our
unpublished data). Detenbeck et al. (418) noted that cystic
changes of the humeral head are a prominent feature. The
spine also presents remarkable changes: widened interver-
tebral spaces, vertebral enlargement, and osteophyte forma-
tion, which are caused by endochondral, marginal, and sub-
ligamentous growth of vertebral bone (425). The lumbosacral
region is very often affected, with symptoms occurring fre-
quently in the cervical spine and rarely in the thoracic spine
(417, 420, 421). The thoracic cage is also profoundly modified
by GH and IGF-I excess as already mentioned (Sections III.C
and III.D). Bluestone et al. (420) reported normal spinal mo-
bility and increased total spine-plus-hip mobility for their
patients compared with controls of a similar age. In a similar
case-control study including 54 patients with acromegaly
studied at diagnosis, we found that spinal mobility was
reduced in 30 patients (55.6%) and 10 controls (18.5%; P 
0.001), whereas 39 patients (72.2%) and 16 controls (29.6%;
P 0.0001) complained of articular symptoms (pain and/or
stiffness) attributable to spinal involvement; in particular, 27
patients (50%) and 10 controls (18.5%; P  0.0001) suffered
from frequent backache at the lumbosacral spine (our un-
published data). The presence of axial pain on objective ex-
amination was found in 32 patients (59.3%) and 15 controls
(27.8%; P  0.002). At radiographs, thoracic cage involve-
ment was found in six patients (11.1%), alterations of the
spinal profile were observed in 37 patients (68.5%) and in 15
controls (27.8%), and increased L2 vertebra diameters were
observed in 34 patients (63%) and none of the controls (our
unpublished data). The increased mobility was interpreted
by Bluestone et al. (420) as being due to the thickening of
intervertebral discs and lax paraspinal ligaments. Ossifica-
tion of the anterior surface of the vertebral bodies is relatively
common, and contributes to increasing their apparent an-
teroposterior diameter. In more severe cases, this ossification
process can bridge the disc space resembling diffuse idio-
pathic skeletal hyperostosis (DISH) syndrome (420, 421, 442).
DISH syndrome has been described in metabolic disorders
such as diabetes mellitus, hyperinsulinemia, and gout (443,
444), but rarely in acromegaly (442). In our series, DISH
features were recorded in 11 patients (20.4%) and none of the
controls; we also found that DISH severity was correlated
with basal and peak glucose levels after glucose load, sug-
FIG. 14. Scheme of the potential progression of the ac-
romegalic arthropathy during the different stages of the
disease.
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gesting a close relationship between metabolic and bone
complications (our unpublished data). Posterior scalloping
of vertebral bodies is also frequently found, whereas facet
joint hypertrophy is unusual (421). Periarticular soft tissue
structures, such as joint capsules and tendons, especially in
the presence of exudative processes, can be carefully inves-
tigated by ultrasonography. This technique revealed that the
thickness of both weight-bearing (knees), and non-weight-
bearing joints (shoulder and wrist) is significantly increased
in patients with active acromegaly compared with controls
(419). Joint thickness was found to be similarly increased in
patients cured by surgery compared with controls (419),
suggesting that even long-term normalization of GH and
IGF-I levels is only partly effective in reversing advanced
arthropathy of acromegaly. Particular mention merits the
well-known prognathism, which is usually accompanied by
the widening of the interdental spaces. In fact, several pa-
tients are referred for evaluation by dentists or oral surgeons.
These changes often result in malocclusion and may lead to
temporomandibular joint syndrome in up to 33% of patients
with acromegaly (421). Less frequent rheumatological dis-
orders include Raynaud’s phenomenon, occurring in 24% of
cases (420), and polymyalgia rheumatica, observed in 4% of
patients (421).
D. The carpal tunnel syndrome
Symptomatic carpal tunnel syndrome is a common con-
dition in acromegaly, with a prevalence from 20–52% (9, 415,
420, 421) up to 64% of patients at presentation (445). Nerve
conduction studies have documented subclinical abnormal-
ities in the vast majority of patients (446, 447). Jenkins et al.
(448) showed by magnetic resonance imaging (MRI) that
patients with symptoms of neuropathy had increased nerve
size and signal intensity compared with asymptomatic pa-
tients, but the two groups did not differ in the volume of
carpal tunnel contents. The predominant pathology of me-
dian neuropathy in acromegaly consisted of increased edema
of the median nerve in the carpal tunnel, rather than extrinsic
compression due to increased volume of the carpal tunnel
contents (448). Clinical symptoms of median neuropathy
likely originate from increased median nerve size within the
carpal tunnel, consistent with swelling of nervous structures.
This hypothesis is supported by the increased signal inten-
sity recorded on T2-weighted images and the rapid reduction
FIG. 15. Radiographic features of abnormalities of the hand and
wrist in a female patient aged 48 yr with an estimated disease du-
ration of 8–10 yr. At the hand, note at terminal phalanges the en-
largement of tuft and bases. At metacarpophalangeal joints, it is
worth noting the widening of some articular spaces, whereas at the
proximal interphalangeal joints there is narrowing of others. Note the
width of some proximal phalanges resembling the presence of “beak-
like” osteophytes at the level of distal interphalangeal joints and at
proximal interphalangeal joints. Periarticular calcific deposits are
also present. At the wrist, note the enlargement of distal radius and
ulna as well as at ulnar styloid. Lateral to the radius, some “beak-like”
osteophytes can be appreciated.
FIG. 16. Radiographic features of bone proliferation at sites of tendon
and ligament attachment to bone (enthesopathy) in a female patient
aged 48 yr with an estimated disease duration of 8–10 yr. Note the
proliferation along the posterior margin of the calcaneus. This is a
proliferative enthesopathy different from the common enthesopathy
occurring in other rheumatic diseases. This latter spondyloarthopa-
thy is characterized by a primary erosive, due to local release of
cytokines, and a secondary proliferative process.
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in nerve size and resolution of symptoms after decrease of
GH levels (448). The chronic impairment of nerve conduction
suggests that edema may damage myelin sheathes (449, 450).
In contrast with the MRI findings in idiopathic carpal tunnel
syndrome, bowing of the flexor retinaculum did not change
in acromegaly, indicating that the overall volume of the
carpal tunnel contents is unaltered (448). Previous studies of
median neuropathy in acromegaly proposed various patho-
genic mechanisms, including an increase in connective tissue
within the carpal tunnel (451), demyelination of Schwann
cells (452), bony or synovial overgrowth of carpal bones
(453), or an increase in extracellular fluid within the tunnel
itself (454). There is no correlation between GH and IGF-I
levels or the duration of acromegaly and the presence of
carpal tunnel syndrome (445–447, 455). Similarly, Jenkins et
al. (448) did not find any correlation between GH or IGF-I
levels and both radiological and electrophysiological mea-
surements, either before or after treatment. Additionally,
hormone levels were equally elevated both in symptomatic
and asymptomatic patients. It should be noted, however, that
nerve swelling decreases after reduction of GH and IGF-I
hypersecretion, therefore suggesting that control of hormone
levels is a prerequisite for regression of nerve abnormalities
(445, 447, 453).
E. Bone mass alterations
Until the end of the 1960s, acromegaly was considered as
a relevant cause of secondary osteoporosis (456), a theory
that paradoxically contradicts the observed stimulatory ef-
fect of GH and IGF-I on osteoblast function. In the 1970s,
several studies contributed to changing this inference by
indicating a potential anabolic effect of GH, at least on the
cortical bone (457, 458). Successively, Seeman et al. (459)
demonstrated that osteoporosis occurs rarely in acromegaly
and thus hypothesized that it could be a consequence of
hypogonadism in a variable number of patients. Character-
istically, acromegaly causes an increase in both bone appo-
sition and resorption (460), but data on bone mass are con-
troversial (457, 459, 461–468). This discordance of results
depends mainly on differences in skeletal sites investigated,
diagnostic equipment used, and grouping of patients re-
gardless of gender and gonadal status. Data on cortical bone
generally show a normal or even increased bone mineral
density (regardless of the gonadal status), although discrep-
ant data are available on the trabecular bone (460). Riggs et
al. (457) first reported increased cortical bone density in the
forearm at a distal site, which is almost entirely composed of
cortical tissue. Increased cortical, but not trabecular, bone
density in the forearm was also reported by Diamond et al.
(461). At the spine and femur, both cortical and trabecular
bone density has been reported to be increased in series
including both hypogonadal and eugonadal patients (464), as
well as only eugonadal patients (468). Differently, bone den-
sity at the spine levels was reported to be normal in other
series including either eugonadal patients (461, 463) or hypo-
and eugonadal patients (461, 465). Indeed, the impact of
hypogonadism should be considered of the utmost impor-
tance in patients with acromegaly when evaluating bone
density. Scillitani et al. (466) reported normal bone density in
the forearm regardless of the gonadal status of patients,
while bone density was increased in the femur in their entire
series of patients. The authors also documented an increased
trabecular bone mass in the spine, but not in the femur or the
forearm, in the series as a whole as well as in the subset of
eugonadal patients. In contrast, at each site examined, hy-
pogonadal patients had values of trabecular bone mass sim-
ilar to those detected in the matched controls (466). Alto-
gether, these data suggest that GH and IGF-I excess induces
an increase of the cortical bone density, independently of
gonadal function, whereas hypogonadism seems to coun-
teract the anabolic effect of GH on the trabecular bone.
F. Effect of GH and IGF-I control on the skeletal system
Whether acromegalic arthropathy can be reversed by con-
trolling GH and IGF-I levels is still questioned. The extensive
structural changes occurring at the joints and the limited
reparative ability of chondrocytes appear to prevent the sig-
nificant improvement of acromegalic arthropathy. However,
surgery or treatment with somatostatin analogs was shown
to be associated with improved symptoms and signs of ac-
romegalic arthropathy (6, 417, 441, 469, 470). Mild to mod-
erate improvement in pain, crepitus, and range of motion has
been reported in the majority of patients treated with oct-
reotide (6). The possibility exists that some of the milder early
changes, such as cartilage thickening and joint space wid-
ening, may resolve with successful early treatment. None-
theless, several reports indicate that symptomatic and func-
tional improvement may occur, although the arthropathic
process itself is irreversible. Podgorski et al. (421) noted that
arthropathy was milder in patients responder than in non-
responder to octreotide, and Layton et al. (417) reported
improvement of symptoms after octreotide treatment, but
objective improvement was observed only in one of nine
patients. Conversely, Dons et al. (415) reported decreased
joint pain in 12 patients and pain worsening in 29 of 47
patients 5 yr after radiotherapy. We recently demonstrated
that cartilage thickness measured by ultrasonography at the
shoulder, wrist, and left knee was significantly decreased
after 6 months of octreotide treatment in a small group of
previously untreated acromegalic patients (419). However,
in neither patients cured for acromegaly nor those receiving
octreotide treatment did cartilage thickness return to values
comparable to healthy subjects (419). In a subsequent study,
we found that thickening of shoulder, wrist, and knee car-
tilages and of heel tendons significantly decreased in all
patients after 12 months of treatment with lanreotide (471).
We also found that the reduction of right shoulder cartilage
thickness by 37% was significantly greater than that observed
at the level of right and left knee cartilages and heel tendons,
ranging in these sites from 14 to 19% (471). More recently, in
a prospective evaluation of joint thickness after 12 months of
octreotide-LAR treatment, we demonstrated that there was
a decrease in the thickness of the shoulder (15.1  3.2%),
wrist (20.5  3.1%), right (22.2  3.4%) and left knee (18.2 
2.8%) in all patients; however, the reduction in joint thickness
at all sites was significantly greater in the patients with con-
trolled disease after octreotide-LAR treatment than in the
uncontrolled ones (Fig. 17) (472). Moreover, values com-
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pared with controls of shoulder and right knee thickening
were found in as high as 61% and 89%, respectively, in
well-controlled patients (472). We did not find any gender
difference (472). Carpal tunnel syndrome is also significantly
improved in most patients after control of GH and IGF-I level
hypersecretion (186, 445, 447, 453), but the underlying patho-
genic mechanisms are unknown (452, 454). Jenkins et al. (448)
showed that the increased nerve size and signal intensity at
MRI improved with treatment of acromegaly in symptomatic
patients, whereas asymptomatic patients experienced no
change or worsening. Because the prevalent pathological
mechanism of median neuropathy in acromegaly is edema of
the perineural sheathes, rather than increased volume of the
carpal tunnel contents, the rapid resolution of edema after
suppression of GH and IGF-I levels is associated with res-
olution of neuropathic symptoms (448). However, when all
findings on acromegalic arthropathy are considered to-
gether, it appears that some early alterations, such as joint
thickness or osteopenia, can be reversed by suppressing GH
and IGF-I levels, whereas later bone complications, such as
osteoarthritis and bone deformities, should be considered
definitive features of the disease.
VII. Summary
Acromegaly is a very peculiar and interesting disease that
engenders intense interest from a wide variety of spheres.
Since its initial definition over 100 yr ago, extraordinary
efforts have been made to control GH levels and the pituitary
tumor in the vast majority of patients. Criteria of cure have
been evolving constantly, and all previous statements should
be revised according with modern criteria of disease control.
It is well accepted that mortality in acromegaly is increased
mostly because of cardiovascular and respiratory diseases.
Whether neoplastic complications may also increase death
rates in acromegaly, as it was formerly theorized, has been
questioned by more recent epidemiological studies. Among
different cardiovascular complications, the most frequent is
biventricular hypertrophy, which occurs independently of
hypertension and metabolic complications but is, in turn,
aggravated by these disorders. Diastolic and systolic dys-
function develops in a variable number of patients, depend-
ing on age and disease duration. Other cardiac disorders,
such as arrhythmias, valve disease, hypertension, athero-
sclerosis, and endothelial dysfunction, have been less char-
acterized, but all appear to be present in acromegaly, de-
picting the so-called “acromegalic cardiomyopathy.”
Control of acromegaly by surgery or pharmacotherapy, es-
pecially somatostatin analogs, improves cardiovascular mor-
bidity. The beneficial effects on the new pharmacotherapy of
acromegaly using a GH-antagonist are still largely unknown.
Besides direct negative effects of GH/IGF-I excess on heart
and vessels, there are other negative effects on glucose and
FIG. 17. Ultrasonographic evaluation of joint thickness before and during octreotide-LAR therapy for 12 months in 30 de novo patients with
active acromegaly. A, Left shoulder; B, left wrist; C, right knee; D, left knee. F, Patients with controlled disease; E, patients with uncontrolled
disease. Data were modified by Ref. 272. Data are shown as mean  SD and were analyzed by the two-way ANOVA.
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lipid metabolism, which also ultimately lead to an increased
cardiovascular risk. The metabolic complications seem to be
more directly due to GH than to IGF-I excess. They affect
virtually all patients with acromegaly, even if glucose and
lipid changes developing at an early stage may not be clin-
ically significant. Although somatostatin analogs were ini-
tially suspected to cause an impairment of glucose tolerance,
the majority of the studies indicate that the control of acro-
megaly improves glucose and lipid alterations. Respiratory
disorders are also important contributors in increasing mor-
tality; the best-characterized respiratory disease is sleep ap-
nea, which is beneficially advantaged by controlling GH and
IGF-I hypersecretion. Ventilatory dysfunction, a less studied
cause of respiratory disorders, recognizes bony changes of
thoracic cage and lung overgrowth as relevant pathogenetic
factors. Improvement after therapy seems hardly achieved.
Earlier evidence that patients with acromegaly have an in-
creased risk of developing malignancies has become more
realistic in recent years. Most studies have reported an in-
creased risk of colonic polyps, which more frequently recur
in patients not controlled after treatment. Malignancies in
other organs have also been described, but less convincingly
than at the gastrointestinal level. Hypertrophy is also com-
mon at different body sites, such as thyroid and prostate. At
the beginning of the disease, hypertrophic changes are likely
to be reversed, whereas patients with long-standing disease
are more prone to develop degenerative changes, such as
nodules and calcifications, which prevent the recovery to the
predisease state. Arthropathy is undoubtedly the most im-
portant cause of morbidity, and functional disability and
bone alterations are highly characteristic of this syndrome.
They involve theoretically all bones and, particularly, the
appendicular and the axial skeleton. Radiographic changes
at different joint sites are more common than symptoms
related to their involvement. As previously stated, there is a
progression in the acromegalic arthropathy resembling that
described for the acromegalic cardiomyopathy or for the
acromegalic features at other organs such as thyroid, breast,
and prostate. At an early stage, cartilage hypertrophy pre-
dominates, and then degenerative changes start until osteo-
arthritis features occur. Arthropathy can be reversed at this
stage, but not if the disease is left untreated.
VIII. Conclusions
Early and modern studies agree on identifying cardiovas-
cular and respiratory complications as the most relevant
causes of the increased risk of mortality in acromegaly.
Doubts have been raised on the relevance of neoplastic com-
plications, and future elucidation of local IGF-I and IGFBP-3
action will contribute to clarifying this issue more ade-
quately. There is enough good evidence to infer that acro-
megaly is currently diagnosed earlier than, for instance, in
the 1930s because patients only rarely present visual field
defects. Indeed, early detection prevents the development of
irreversible complications of the disease, including cardio-
myopathy, respiratory dysfunction, and arthropathy. Clear
evidence also exists that, in the early stage, all of these dis-
orders can be totally reversed. Whether improvement in
morbidity will correspond to a similar improvement in mor-
tality, although highly likely, still awaits further demonstra-
tion by large prospective studies.
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